

University of Groningen

Regional diversity in oligodendrocyte progenitor cells

Lentferink, Dennis Hendrikus

DOI:
[10.33612/diss.165785295](https://doi.org/10.33612/diss.165785295)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Lentferink, D. H. (2021). *Regional diversity in oligodendrocyte progenitor cells: implications for remyelination in grey and white matter*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.165785295>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

References



References

1. Nave, K.-A. Myelination and the trophic support of long axons. *Nat. Rev. Neurosci.* **11**, 275–283 (2010). doi:10.1038/nrn2797
2. Simons, M. & Nave, K.-A. Oligodendrocytes: Myelination and axonal support. *Cold Spring Harb. Perspect. Biol.* **8**, a020479 (2016). doi:10.1101/cshperspect.a020479
3. Franklin, R. J. M. & ffrench-Constant, C. Remyelination in the CNS: From biology to therapy. *Nat. Rev. Neurosci.* **9**, 839–855 (2008). doi:10.1038/nrn2480
4. Compston, A. & Coles, A. Multiple sclerosis. *Lancet* **372**, 1502–1517 (2008). doi:10.1016/S0140-6736(08)61620-7
5. Korn, T. Pathophysiology of multiple sclerosis. *J. Neurol.* **255 Suppl**, 2–6 (2008). doi:10.1007/s00415-008-6001-2
6. Hostenbach, S., Cambron, M., D'haeseleer, M., Kooijman, R. & De Keyser, J. Astrocyte loss and astrogliosis in neuroinflammatory disorders. *Neurosci. Lett.* **565**, 39–41 (2014). doi:10.1016/j.neulet.2013.10.012
7. van Waesberghe, J. H. T. M. *et al.* Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. *Ann. Neurol.* **46**, 747–754 (1999). doi:10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4
8. Trapp, B. D. *et al.* Axonal transection in the lesions of multiple sclerosis. *N. Engl. J. Med.* **338**, 278–285 (1998). doi:10.1056/NEJM199801293380502
9. Bjartmar, C., Kidd, G. J., Mørk, S. J., Rudick, R. & Trapp, B. D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. *Ann. Neurol.* **48**, 893–901 (2000). doi:10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B
10. Lassmann, H. & Van Horssen, J. The molecular basis of neurodegeneration in multiple sclerosis. *FEBS Letters* **585**, 3715–3723 (2011). doi:10.1016/j.febslet.2011.08.004
11. Luchetti, S. *et al.* Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis. *Acta Neuropathol.* **135**, 511–528 (2018). doi:10.1007/s00401-018-1818-y
12. Patrikios, P. *et al.* Remyelination is extensive in a subset of multiple sclerosis patients. *Brain* **129**, 3165–72 (2006). doi:10.1093/brain/awl217
13. Patani, R., Balaratnam, M., Vora, A. & Reynolds, R. Remyelination can be extensive in multiple sclerosis despite a long disease course. *Neuropathol. Appl. Neurobiol.* **33**, 277–87 (2007). doi:10.1111/j.1365-2990.2007.00805.x
14. Sim, F. J., Zhao, C., Penderis, J. & Franklin, R. J. M. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. *J. Neurosci.* **22**, 2451–9 (2002). doi:20026217
15. Kuhlmann, T. *et al.* Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. *Brain* **131**, 1749–58 (2008). doi:10.1093/brain/awn096
16. Franklin, R. J. M. Why does remyelination fail in multiple sclerosis? *Nat. Rev. Neurosci.* **3**, 705–714 (2002). doi:10.1038/nrn917
17. Lucchinetti, C. F. *et al.* A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. *Brain* **122**, 2279–2295 (1999). doi:10.1093/brain/122.12.2279
18. Chang, A., Tourtellotte, W. W., Rudick, R. & Trapp, B. D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. *N. Engl. J. Med.* **346**, 165–173 (2002). doi:10.1056/NEJMoao10994
19. Plemel, J. R., Liu, W.-Q. & Yong, V. W. Remyelination therapies: A new direction and challenge in multiple sclerosis. *Nat. Rev. Drug Discov.* **16**, 617–634 (2017). doi:10.1038/nrd.2017.115
20. Jäkel, S. *et al.* Altered human oligodendrocyte heterogeneity in multiple sclerosis. *Nature* **566**, 543–547 (2019). doi:10.1038/s41586-019-0903-2
21. Schirmer, L. *et al.* Neuronal vulnerability and multilineage diversity in multiple sclerosis. *Nature* **573**, 75–82 (2019). doi:10.1038/s41586-019-1404-z
22. Yeung, M. S. Y. *et al.* Dynamics of oligodendrocyte generation in multiple sclerosis. *Nature* **566**, 538–542 (2019). doi:10.1038/s41586-018-0842-3
23. Neely, S. *et al.* New oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that survive demyelination. *bioRxiv* 2020.05.22.110551 (2020). doi:10.1101/2020.05.22.110551
24. Gudi, V. *et al.* Regional differences between grey and white matter in cuprizone induced demyelination. *Brain Res.* **1283**, 127–138 (2009). doi:10.1016/j.brainres.2009.06.005
25. Bai, C. B. *et al.* A mouse model for testing remyelinating therapies. *Exp. Neurol.* **283**, 330–340 (2016). doi:10.1016/j.expneurol.2016.06.033
26. Chang, A. *et al.* Cortical remyelination: A new target for repair therapies in multiple sclerosis. *Ann. Neurol.* **72**, 918–926 (2012). doi:10.1002/ana.23693
27. Strijbis, E. M. M., Kooi, E.-J., van der Valk, P. & Geurts, J. J. G. Cortical remyelination is heterogeneous in multiple sclerosis. *J. Neuropathol. Exp. Neurol.* **76**, 390–401 (2017). doi:10.1093/jnen/nlx023
28. Marques, S. *et al.* Transcriptional convergence of oligodendrocyte lineage progenitors during development. *Dev. Cell* **46**, 504–517.e7 (2018). doi:10.1016/j.devcel.2018.07.005
29. Falcão, A. M. *et al.* Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. *Nat. Med.* **24**, 1837–1844 (2018). doi:10.1038/s41591-018-0236-y
30. Masuda, T., Sankowski, R., Staszewski, O. & Prinz, M. Microglia heterogeneity in the single-cell era. *Cell Rep.* **30**, 1271–1281 (2020). doi:10.1016/j.celrep.2020.01.010
31. Werkman, I. L., Kövilein, J., de Jonge, J. C. & Baron, W. Impairing committed cholesterol biosynthesis in white matter astrocytes, but not grey matter astrocytes, enhances in vitro myelination. *J. Neurochem.* (2020). doi:10.1111/jnc.15113
32. Prins, M. *et al.* Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients. *Acta Neuropathol. Commun.* **2**, 98 (2014). doi:10.1186/s40478-014-0098-6
33. Goursaud, S., Kozlova, E. N., Maloteaux, J.-M. & Hermans, E. Cultured astrocytes derived from corpus callosum or cortical grey matter show distinct glutamate handling properties. *J. Neurochem.* **108**, 1442–1452 (2009). doi:10.1111/j.1471-4159.2009.05889.x
34. Marques, S. *et al.* Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. *Science* **352**, 1326–1329 (2016). doi:10.1126/science.aaf6463

35. van der Star, B. J. *et al.* In vitro and in vivo models of multiple sclerosis. *CNS Neurol. Disord. - Drug Targets* **11**, 570–588 (2012). doi:10.2174/187152712801661284
36. Psachoulia, K., Jamen, F., Young, K. M. & Richardson, W. D. Cell cycle dynamics of NG2 cells in the postnatal and ageing brain. *Neuron Glia Biol.* **5**, 57–67 (2009). doi:10.1017/S1740925X09990354
37. Spitzer, S. O. *et al.* Oligodendrocyte progenitor cells become regionally diverse and heterogeneous with age. *Neuron* **101**, 459–471.e5 (2019). doi:10.1016/j.neuron.2018.12.020
38. Dimou, L., Simon, C., Kirchhoff, F., Takebayashi, H. & Götz, M. Progeny of Olig2-expressing progenitors in the gray and white matter of the adult mouse cerebral cortex. *J. Neurosci.* **28**, 10434–10442 (2008). doi:10.1523/JNEUROSCI.2831-08.2008
39. Mallon, B. S., Elizabeth Shick, H., Kidd, G. J. & Macklin, W. B. Proteolipid promoter activity distinguishes two populations of NG2-positive cells throughout neonatal cortical development. *J. Neurosci.* **22**, 876–885 (2002). doi:10.1523/jneurosci.22-03-00876.2002
40. Keirstead, H. S., Levine, J. M. & Blakemore, W. F. Response of the oligodendrocyte progenitor cell population (Defined by NG2 labelling) to demyelination of the adult spinal cord. *Glia* **22**, 161–170 (1998). doi:10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A
41. Lytle, J. M., Chittajallu, R., Wrathall, J. R. & Gallo, V. NG2 cell response in the CNP-EGFP mouse after contusive spinal cord injury. *Glia* **57**, 270–285 (2009). doi:10.1002/glia.20755
42. Chittajallu, R., Aguirre, A. & Gallo, V. NG2-positive cells in the mouse white and grey matter display distinct physiological properties. *J. Physiol.* **561**, 109–122 (2004). doi:10.1113/jphysiol.2004.074252
43. Káradóttir, R. T., Hamilton, N. B., Bakiri, Y. & Attwell, D. Spiking and nonspiking classes of oligodendrocyte precursor glia in CNS white matter. *Nat. Neurosci.* **11**, 450–456 (2008). doi:10.1038/nn2060
44. Viganò, F., Möbius, W., Götz, M. & Dimou, L. Transplantation reveals regional differences in oligodendrocyte differentiation in the adult brain. *Nat. Neurosci.* **16**, 1370–2 (2013). doi:10.1038/nn.3503
45. Gingele, S. *et al.* Delayed demyelination and impaired remyelination in aged mice in the cuprizone model. *Cells* **9**, (2020). doi:10.3390/cells9040945
46. Shields, S. A., Gilson, J. M., Blakemore, W. F. & Franklin, R. J. M. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. *Glia* **28**, 77–83 (1999). doi:10.1002/(SICI)1098-1136(199910)28:1<77::AID-GLIA9>3.0.CO;2-F
47. Neumann, B. *et al.* Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. *Cell Stem Cell* **25**, 473–485.e8 (2019). doi:10.1016/j.stem.2019.08.015
48. Miyamoto, N. *et al.* Age-related decline in oligodendrogenesis retards white matter repair in mice. *Stroke* **44**, 2573–2578 (2013). doi:10.1161/STROKEAHA.113.001530
49. Lloyd, A. F. & Miron, V. E. The pro-remyelination properties of microglia in the central nervous system. *Nature Reviews Neurology* **15**, 447–458 (2019). doi:10.1038/s41582-019-0184-2
50. Rawji, K. S., Gonzalez Martinez, G. A., Sharma, A. & Franklin, R. J. M. The role of astrocytes in remyelination. *Trends in Neurosciences* **43**, 596–607 (2020). doi:10.1016/j.tins.2020.05.006
51. Kotter, M. R. N., Li, W.-W., Zhao, C. & Franklin, R. J. M. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. *J. Neurosci.* **26**, 328–332 (2006). doi:10.1523/JNEUROSCI.2615-05.2006
52. Miron, V. E. *et al.* M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat. Neurosci.* **16**, 1211–1218 (2013). doi:10.1038/nn.3469
53. Boven, L. A. *et al.* Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. *Brain* **129**, 517–526 (2006). doi:10.1093/brain/awh707
54. Bogie, J. F. J., Stinissen, P., Hellings, N. & Hendriks, J. J. A. Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation. *J. Neuroinflammation* **8**, (2011). doi:10.1186/1742-2094-8-85
55. Bogie, J. F. J. *et al.* Myelin-derived lipids modulate macrophage activity by Liver X Receptor activation. *PLoS One* **7**, e44998 (2012). doi:10.1371/journal.pone.0044998
56. Bogie, J. F. J. *et al.* Myelin alters the inflammatory phenotype of macrophages by activating PPARs. *Acta Neuropathol. Commun.* **2**, (2014). doi:10.1186/2051-5960-1-43
57. Moyon, S. *et al.* Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. *J. Neurosci.* **35**, 4–20 (2015). doi:10.1523/JNEUROSCI.0849-14.2015
58. Cannella, B. & Raine, C. S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. *Ann. Neurol.* **37**, 424–435 (1995). doi:10.1002/ana.410370404
59. Falcón-Urrutia, P., Carrasco, C. M., Lois, P., Palma, V. & Roth, A. D. Shh signaling through the primary cilium modulates rat oligodendrocyte differentiation. *PLoS One* **10**, e0133567 (2015). doi:10.1371/journal.pone.0133567
60. Kessaris, N. *et al.* Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. *Nat. Neurosci.* **9**, 173–9 (2006). doi:10.1038/nn1620
61. Solaro, C. *et al.* The changing face of multiple sclerosis: Prevalence and incidence in an aging population. *Mult. Scler.* **21**, 1244–1250 (2015). doi:10.1177/1352458514561904
62. Tobin, W. O. *et al.* Clinical–radiological–pathological spectrum of central nervous system–idiopathic inflammatory demyelinating disease in the elderly. *Mult. Scler.* **23**, 1204–1213 (2017). doi:10.1177/1352458516675748
63. Eisenbarth, G. S., Walsh, F. S. & Nirenberg, M. Monoclonal antibody to a plasma membrane antigen of neurons. *Proc. Natl. Acad. Sci.* **76**, 4913–4917 (1979). doi:10.1073/pnas.76.10.4913
64. Windrem, M. S. *et al.* Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. *Nat. Med.* **10**, 93–97 (2004). doi:10.1038/nm974
65. Schnitzer, J. & Schachner, M. Cell type specificity of a neural cell surface antigen recognized by the monoclonal antibody A2B5. *Cell Tissue Res.* **224**, 625–636 (1982). doi:10.1007/BF00213757
66. Abney, E. R., Williams, B. P. & Raff, M. C. Tracing the development of oligodendrocytes from precursor cells using monoclonal antibodies, fluorescence-activated cell sorting, and cell culture. *Dev. Biol.* **100**, 166–171 (1983). doi:10.1016/0012-1606(83)90207-5
67. Raff, M. C., Abney, E. R., Cohen, J., Lindsay, R. & Noble, M. Two types of astrocytes in cultures of developing rat white matter: Differences in morphology, surface gangliosides, and growth characteristics. *J. Neurosci.* **3**, 1289–1300 (1983). doi:10.1523/jneurosci.03-06-01289.1983

68. Azevedo, F. A. C. *et al.* Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. *J. Comp. Neurol.* **513**, 532–541 (2009). doi:10.1002/cne.21974
69. von Bartheld, C. S., Bahney, J. &erculano-Houzel, S. The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting. *Journal of Comparative Neurology* **524**, 3865–3895 (2016). doi:10.1002/cne.24040
70. Hydén, H. & Pigon, A. A cytophysiological study of the functional relationship between oligodendroglial cells and nerve cells of deiters' nucleus. *J. Neurochem.* **6**, 57–72 (1960). doi:10.1111/j.1471-4159.1960.tb13449.x
71. Bear, M. F., Connors, B. W. & Paradiso, M. A. *Neuroscience: exploring the brain.* (Lippincott Williams & Wilkins, 2007).
72. Kryspin-Exner, W. Über die Architektur der Glia im Zentralnervensystem des Menschen und der Säugetiere. *Proc 1st Intern. Congr Neuropath* **3**, 504–510 (1952).
73. Pelvig, D. P., Pakkenberg, H., Regeur, L., Oster, S. & Pakkenberg, B. Neocortical glial cell numbers in Alzheimer's disease. *Dement. Geriatr. Cogn. Disord.* **16**, 212–219 (2003). doi:10.1159/000072805
74. Verkhratsky, A. & Butt, A. M. *Glial physiology and pathophysiology. Glial Physiology and Pathophysiology* (John Wiley & Sons, Ltd, 2013). doi:10.1002/9781118402061
75. Pope, A. The intralaminar distribution of dipeptidase activity in human frontal isocortex. *J. Neurochem.* **4**, 31–41 (1959). doi:10.1111/j.1471-4159.1959.tb13171.x
76. Foerster, S., Hill, M. F. E. & Franklin, R. J. M. Diversity in the oligodendrocyte lineage: Plasticity or heterogeneity? *Glia* **67**, glia.23607 (2019). doi:10.1002/glia.23607
77. Nave, K.-A. Myelination and support of axonal integrity by glia. *Nature* **468**, 244–52 (2010). doi:10.1038/nature09614
78. Jang, M., Gould, E., Xu, J., Kim, E. J. & Kim, J. H. Oligodendrocytes regulate presynaptic properties and neurotransmission through BDNF signaling in the mouse brainstem. *Elife* **8**, (2019). doi:10.7554/eLife.42156
79. Sakry, D. *et al.* Oligodendrocyte precursor cells modulate the neuronal network by activity-dependent ectodomain cleavage of glial NG2. *PLoS Biol.* **12**, e1001993 (2014). doi:10.1371/journal.pbio.1001993
80. Pringle, N. P., Mudhar, H. S., Collarini, E. J. & Richardson, W. D. PDGF receptors in the rat CNS: During late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. *Development* **115**, 535–551 (1992).
81. Nishiyama, A., Lin, X.-H., Giese, N., Heldin, C.-H. & Stallcup, W. B. Co-localization of NG2 proteoglycan and PDGF α -receptor on O2A progenitor cells in the developing rat brain. *J. Neurosci. Res.* **43**, 299–314 (1996). doi:10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E
82. Dawson, M. R. L., Polito, A., Levine, J. M. & Reynolds, R. NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. *Mol. Cell. Neurosci.* **24**, 476–488 (2003). doi:10.1016/S1044-7431(03)00210-0
83. Karram, K. *et al.* NG2-expressing cells in the nervous system revealed by the NG2-EYFP-knockin mouse. *genesis* **46**, 743–757 (2008). doi:10.1002/dvg.20440
84. Rivers, L. E. *et al.* PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. *Nat. Neurosci.* **11**, 1392–401 (2008). doi:10.1038/nn.2220
85. Fard, M. K. *et al.* BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. *Sci. Transl. Med.* **9**, eaam7816 (2017). doi:10.1126/scitranslmed.aam7816
86. Zhang, Y. *et al.* An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci.* **34**, 11929–11947 (2014). doi:10.1523/JNEUROSCI.1860-14.2014
87. Kuhn, S., Gritti, L., Crooks, D. & Dombrowski, Y. Oligodendrocytes in development, myelin generation and beyond. *Cells* **8**, 1424 (2019). doi:10.3390/cells811424
88. Baumann, N. & Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. *Physiol. Rev.* **81**, 871–927 (2001). doi:10.1152/physrev.2001.81.2.871
89. Jahn, O., Tenzer, S. & Werner, H. B. Myelin proteomics: Molecular anatomy of an insulating sheath. *Mol. Neurobiol.* **40**, 55–72 (2009). doi:10.1007/s12035-009-8071-2
90. Redwine, J. M. & Armstrong, R. C. In vivo proliferation of oligodendrocyte progenitors expressing PDGF α R during early remyelination. *J. Neurobiol.* **37**, 413–428 (1998). doi:10.1002/(SICI)1097-4695(199811)37:3<413::AID-NEU7>3.0.CO;2-8
91. Franklin, R. J. M. & Blakemore, W. F. To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions? *Mult. Scler. J.* **3**, 84–87 (1997). doi:10.1177/135245859700300205
92. Almeida, R. G. The rules of attraction in central nervous system myelination. *Front. Cell. Neurosci.* **12**, 367 (2018). doi:10.3389/fncel.2018.00367
93. Fancy, S. P. J. *et al.* Overcoming remyelination failure in multiple sclerosis and other myelin disorders. *Exp. Neurol.* **225**, 18–23 (2010). doi:10.1016/j.expneurol.2009.12.020
94. Morell, P. & Toews, A. D. In vivo metabolism of oligodendroglial lipids. in *Oligodendroglia* 47–86 (Springer US, 1984). doi:10.1007/978-1-4757-6066-8_2
95. Cammer, W. Oligodendrocyte-associated enzymes. in *Oligodendroglia* 199–232 (Springer US, 1984). doi:10.1007/978-1-4757-6066-8_6
96. Thorburne, S. K. & Juurlink, B. H. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. *J. Neurochem.* **67**, 1014–22 (1996). doi:10.1046/j.1471-4159.1996.67031014.x
97. Connor, J. R. & Menzies, S. L. Relationship of iron to oligodendrocytes and myelination. *Glia* **17**, 83–93 (1996). doi:10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7
98. Hughes, E. G., Kang, S. H., Fukaya, M. & Bergles, D. E. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. *Nat. Neurosci.* **16**, 668–76 (2013). doi:10.1038/nn.3390
99. Ohya, W., Funakoshi, H., Kurosawa, T. & Nakamura, T. Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat. *Brain Res.* **1147**, 51–65 (2007). doi:10.1016/j.brainres.2007.02.045
100. Geha, S. *et al.* NG2+/Olig2+ cells are the major cycle-related cell population of the adult human normal brain. *Brain Pathol.* **20**, 399–411 (2010). doi:10.1111/j.1750-3639.2009.00295.x

101. Young, K. M. *et al.* Oligodendrocyte dynamics in the healthy adult CNS: Evidence for myelin remodeling. *Neuron* **77**, 873–885 (2013). doi:10.1016/j.neuron.2013.01.006
102. Wolswijk, G. & Noble, M. Identification of an adult-specific glial progenitor cell. *Development* **105**, 387–400 (1989).
103. Wren, D., Wolswijk, G. & Noble, M. In vitro analysis of the origin and maintenance of O-2Aadult progenitor cells. *J. Cell Biol.* **116**, 167–176 (1992). doi:10.1083/jcb.116.1.167
104. Perlman, K. *et al.* Developmental trajectory of oligodendrocyte progenitor cells in the human brain revealed by single cell RNA sequencing. *Glia* (2020). doi:10.1002/glia.23777
105. Allen, N. J. & Eroglu, C. Cell biology of astrocyte-synapse interactions. *Neuron* **96**, 697–708 (2017). doi:10.1016/j.neuron.2017.09.056
106. Chung, W.-S. *et al.* Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. *Nature* **504**, 394–400 (2013). doi:10.1038/nature12776
107. Clarke, L. E. & Barres, B. A. Glia keep synapse distribution under wraps. *Cell* **154**, 267–268 (2013). doi:10.1016/j.cell.2013.06.045
108. Alvarez, J. I., Katayama, T. & Prat, A. Glial influence on the blood brain barrier. *Glia* **61**, 1939–58 (2013). doi:10.1002/glia.22575
109. Camargo, N. *et al.* Oligodendroglial myelination requires astrocyte-derived lipids. *PLoS Biol.* **15**, e1002605 (2017). doi:10.1371/journal.pbio.1002605
110. Saher, G. *et al.* High cholesterol level is essential for myelin membrane growth. *Nat. Neurosci.* **8**, 468–75 (2005). doi:10.1038/nn1426
111. Schitine, C., Nogaroli, L., Costa, M. R. & Hedin-Pereira, C. Astrocyte heterogeneity in the brain: From development to disease. *Front. Cell. Neurosci.* **9**, 76 (2015). doi:10.3389/fncel.2015.00076
112. Rowitch, D. H. & Kriegstein, A. R. Developmental genetics of vertebrate glial-cell specification. *Nature* **468**, 214–222 (2010). doi:10.1038/nature09611
113. Bayraktar, O. A., Fuentealba, L. C., Alvarez-Buylla, A. & Rowitch, D. H. Astrocyte development and heterogeneity. *Cold Spring Harb. Perspect. Biol.* **7**, a020362 (2014). doi:10.1101/cshperspect.a020362
114. Molofsky, A. V. & Deneen, B. Astrocyte development: A guide for the perplexed. *Glia* **63**, 1320–1329 (2015). doi:10.1002/glia.22836
115. Ge, W.-P., Miyawaki, A., Gage, F. H., Jan, Y. N. & Jan, L. Y. Local generation of glia is a major astrocyte source in postnatal cortex. *Nature* **484**, 376–380 (2012). doi:10.1038/nature10959
116. Bandeira, F., Lent, R. & Herculano-Houzel, S. Changing numbers of neuronal and non-neuronal cells underlie postnatal brain growth in the rat. *Proc. Natl. Acad. Sci.* **106**, 14108–14113 (2009). doi:10.1073/pnas.0804650106
117. Taft, J. R., Vertes, R. P. & Perry, G. W. Distribution of GFAP+ astrocytes in adult and neonatal rat brain. *Int. J. Neurosci.* **115**, 1333–1343 (2005). doi:10.1080/00207450590934570
118. Tsai, H. *et al.* Regional astrocyte allocation regulates CNS synaptogenesis and repair. *Science* **337**, 358–362 (2012). doi:10.1126/science.1222381
119. Anthony, T. E., Klein, C., Fishell, G. & Heintz, N. Radial glia serve as neuronal progenitors in all regions of the central nervous system. *Neuron* **41**, 881–890 (2004). doi:10.1016/S0896-6273(04)00140-0
120. Owada, Y., Yoshimoto, T. & Kondo, H. Increased expression of the mRNA for brain- and skin-type but not heart-type fatty acid binding proteins following kainic acid systemic administration in the hippocampal glia of adult rats. *Mol. Brain Res.* **42**, 156–160 (1996). doi:10.1016/S0169-328X(96)00182-9
121. Pringle, N. P. *et al.* Fgfr3 expression by astrocytes and their precursors: evidence that astrocytes and oligodendrocytes originate in distinct neuroepithelial domains. *Development* **130**, 93–102 (2003). doi:10.1242/dev.00184
122. Shibata, T. *et al.* Glutamate transporter GLAST is expressed in the radial glia-astrocyte lineage of developing mouse spinal cord. *J. Neurosci.* **17**, 9212–9219 (1997). doi:10.1523/jneurosci.17-23-09212.1997
123. Cahoy, J. D. *et al.* A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. *J. Neurosci.* **28**, 264–278 (2008). doi:10.1523/JNEUROSCI.4178-07.2008
124. Molofsky, A. V. *et al.* Astrocytes and disease: a neurodevelopmental perspective. *Genes Dev.* **26**, 891–907 (2012). doi:10.1101/gad.188326.112
125. Stolt, C. C. *et al.* The Sox9 transcription factor determines glial fate choice in the developing spinal cord. *Genes Dev.* **17**, 1677–89 (2003). doi:10.1101/gad.259003
126. Miller, R. H. & Raff, M. C. Fibrous and protoplasmic astrocytes are biochemically and developmentally distinct. *J. Neurosci.* **4**, 585–592 (1984). doi:10.1523/jneurosci.04-02-00585.1984
127. Dahl, D. & Bignami, A. Immunohistological localization of desmin, the muscle-type 100 A filament protein, in rat astrocytes and Müller glia. *J. Histochem. Cytochem.* **30**, 207–213 (1982). doi:10.1177/30.3.7037941
128. Pixley, S. K. & de Vellis, J. Transition between immature radial glia and mature astrocytes studied with a monoclonal antibody to vimentin. *Brain Res.* **317**, 201–9 (1984). doi:10.1016/0165-3806(84)90097-x
129. Hirako, Y. *et al.* Characterization of mammalian synemin, an intermediate filament protein present in all four classes of muscle cells and some neuroglial cells: co-localization and interaction with type III intermediate filament proteins and keratins. *Cell Tissue Res.* **313**, 195–207 (2003). doi:10.1007/s00441-003-0732-2
130. Bignami, A., Eng, L. F., Dahl, D. & Uyeda, C. T. Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. *Brain Res.* **43**, 429–435 (1972). doi:10.1016/0006-8993(72)90398-8
131. Schachner, M., Hedley-Whyte, E. T., Hsu, D. W., Schoonmaker, G. & Bignami, A. Ultrastructural localization of glial fibrillary acidic protein in mouse cerebellum by immunoperoxidase labeling. *J. Cell Biol.* **75**, 67–73 (1977). doi:10.1083/jcb.75.1.67
132. Kimelberg, H. K. The problem of astrocyte identity. *Neurochem. Int.* **45**, 191–202 (2004). doi:10.1016/j.neuint.2003.08.015

133. Bushong, E. A., Martone, M. E. & Ellisman, M. H. Maturation of astrocyte morphology and the establishment of astrocyte domains during postnatal hippocampal development. *Int. J. Dev. Neurosci.* **22**, 73–86 (2004). doi:10.1016/j.ijdevneu.2003.12.008
134. Boisvert, M. M., Erikson, G. A., Shokhirev, M. N. & Allen, N. J. The aging astrocyte transcriptome from multiple regions of the mouse brain. *Cell Rep.* **22**, 269 (2018). doi:10.1016/j.celrep.2017.12.039
135. Cohen, J. & Torres, C. Astrocyte senescence: Evidence and significance. *Aging Cell* **18**, e12937 (2019). doi:10.1111/ace1.12937
136. Clarke, L. E. *et al.* Normal aging induces A1-like astrocyte reactivity. *Proc. Natl. Acad. Sci.* **115**, E1896–E1905 (2018). doi:10.1073/pnas.1800165115
137. Baracska, K. L., Duchala, C. S., Miller, R. H., Macklin, W. B. & Trapp, B. D. Oligodendrogenesis is differentially regulated in gray and white matter of jimpy mice. *J. Neurosci. Res.* **70**, 645–54 (2002). doi:10.1002/jnr.10418
138. Winkler, C. C. & Franco, S. J. Loss of Shh signaling in the neocortex reveals heterogeneous cell recovery responses from distinct oligodendrocyte populations. *Dev. Biol.* **452**, 55–65 (2019). doi:10.1016/j.ydbio.2019.04.016
139. Dimou, L. *et al.* Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. *J. Neurosci.* **26**, 5591–5603 (2006). doi:10.1523/JNEUROSCI.1103-06.2006
140. Kang, S. H., Fukaya, M., Yang, J. K., Rothstein, J. D. & Bergles, D. E. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. *Neuron* **68**, 668–81 (2010). doi:10.1016/j.neuron.2010.09.009
141. Zhu, X. *et al.* Age-dependent fate and lineage restriction of single NG2 cells. *Development* **138**, 745–753 (2011). doi:10.1242/dev.047951
142. Gensert, J. M. & Goldman, J. E. Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter. *J. Neurobiol.* **48**, 75–86 (2001). doi:10.1002/neu.1043
143. Lin, G., Mela, A., Guilfoyle, E. M. & Goldman, J. E. Neonatal and adult O4⁺ oligodendrocyte lineage cells display different growth factor responses and different gene expression patterns. *J. Neurosci. Res.* **87**, 3390–3402 (2009). doi:10.1002/jnr.22065
144. Lentferink, D. H., Jongsma, J. M., Werkman, I. & Baron, W. Grey matter OPCs are less mature and less sensitive to IFN γ than white matter OPCs: Consequences for remyelination. *Sci. Rep.* **8**, 2113 (2018). doi:10.1038/s41598-018-19934-6
145. Guo, F. *et al.* Pyramidal neurons are generated from oligodendroglial progenitor cells in adult piriform cortex. *J. Neurosci.* **30**, 12036–12049 (2010). doi:10.1523/JNEUROSCI.1360-10.2010
146. Zhu, X., Bergles, D. E. & Nishiyama, A. NG2 cells generate both oligodendrocytes and gray matter astrocytes. *Development* **135**, 145–157 (2007). doi:10.1242/dev.004895
147. Leong, S. Y. *et al.* Heterogeneity of oligodendrocyte progenitor cells in adult human brain. *Ann. Clin. Transl. Neurol.* **1**, 272–83 (2014). doi:10.1002/acn3.55
148. Hill, R. A., Patel, K. D., Medved, J., Reiss, A. M. & Nishiyama, A. NG2 cells in white matter but not gray matter proliferate in response to PDGF. *J. Neurosci.* **33**, 14558–14566 (2013). doi:10.1523/JNEUROSCI.2001-12.2013
149. Trapp, B. D., Nishiyama, A., Cheng, D. & Macklin, W. B. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. *J. Cell Biol.* **137**, 459–468 (1997). doi:10.1083/jcb.137.2.459
150. Chen, P., Cai, W., Wang, L. & Deng, Q. A morphological and electrophysiological study on the postnatal development of oligodendrocyte precursor cells in the rat brain. *Brain Res.* **1243**, 27–37 (2008). doi:10.1016/j.brainres.2008.09.029
151. Chang, A., Nishiyama, A., Peterson, J., Prineas, J. W. & Trapp, B. D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J. Neurosci.* **20**, 6404–6412 (2000). doi:10.1523/jneurosci.20-17-06404.2000
152. Barres, B. A. & Raff, M. C. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. *Nature* **361**, 258–260 (1993). doi:10.1038/361258a0
153. Knutson, P., Ghiani, C. A., Zhou, J.-M., Gallo, V. & McBain, C. J. K⁺ channel expression and cell proliferation are regulated by intracellular sodium and membrane depolarization in oligodendrocyte progenitor cells. *J. Neurosci.* **17**, 2669–2682 (1997). doi:10.1523/JNEUROSCI.17-08-02669.1997
154. Clarke, L. E. *et al.* Properties and fate of oligodendrocyte progenitor cells in the corpus callosum, motor cortex, and piriform cortex of the mouse. *J. Neurosci.* **32**, 8173–8185 (2012). doi:10.1523/JNEUROSCI.0928-12.2012
155. Lundgaard, I. *et al.* Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. *PLoS Biol.* **11**, e1001743 (2013). doi:10.1371/journal.pbio.1001743
156. Gautier, H. O. B. *et al.* Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. *Nat. Commun.* **6**, 8518 (2015). doi:10.1038/ncomms9518
157. Dawson, M. R. L., Levine, J. M. & Reynolds, R. NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? *J. Neurosci. Res.* **61**, 471–9 (2000). doi:10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.0.CO;2-N
158. Abe, H. *et al.* Developmental cuprizone exposure impairs oligodendrocyte lineages differentially in cortical and white matter tissues and suppresses glutamatergic neurogenesis signals and synaptic plasticity in the hippocampal dentate gyrus of rats. *Toxicol. Appl. Pharmacol.* **290**, 10–20 (2016). doi:10.1016/j.taap.2015.11.006
159. Zeldich, E., Chen, C. Di, Avila, R., Medicetty, S. & Abraham, C. R. The anti-aging protein Klotho enhances remyelination following cuprizone-induced demyelination. *J. Mol. Neurosci.* **57**, 185–196 (2015). doi:10.1007/s12031-015-0598-2
160. Tripathi, R. B. *et al.* Dorsally and ventrally derived oligodendrocytes have similar electrical properties but myelinate preferred tracts. *J. Neurosci.* **31**, 6809–6819 (2011). doi:10.1523/JNEUROSCI.6474-10.2011
161. Marisca, R. *et al.* Functionally distinct subgroups of oligodendrocyte precursor cells integrate neural activity and execute myelin formation. *Nat. Neurosci.* **23**, (2020). doi:10.1038/s41593-019-0581-2
162. McKenzie, I. A. *et al.* Motor skill learning requires active central myelination. *Science* **346**, 318–22 (2014). doi:10.1126/science.1254960
163. Levine, J. M., Stincone, F. & Lee, Y.-S. Development and differentiation of glial precursor cells in the rat cerebellum. *Glia* **7**, 307–321 (1993). doi:10.1002/glia.440070406

164. Woodruff, R. H., Fruttiger, M., Richardson, W. D. & Franklin, R. J. M. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. *Mol. Cell. Neurosci.* **25**, 252–62 (2004). doi:10.1016/j.mcn.2003.10.014
165. Bengtsson, S. L. *et al.* Extensive piano practicing has regionally specific effects on white matter development. *Nat. Neurosci.* **8**, 1148–50 (2005). doi:10.1038/nn1516
166. Scholz, J., Klein, M. C., Behrens, T. E. J. & Johansen-Berg, H. Training induces changes in white-matter architecture. *Nat. Neurosci.* **12**, 1370–1371 (2009). doi:10.1038/nn.2412
167. Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. *Nat. Neurosci.* **21**, 696–706 (2018). doi:10.1038/s41593-018-0121-5
168. Hill, R. A., Li, A. M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain. *Nat. Neurosci.* **21**, 683–695 (2018). doi:10.1038/s41593-018-0120-6
169. Mitew, S. *et al.* Pharmacogenetic stimulation of neuronal activity increases myelination in an axon-specific manner. *Nat. Commun.* **9**, 306 (2018). doi:10.1038/s41467-017-02719-2
170. Auer, F., Vagionitis, S. & Czopka, T. Evidence for myelin sheath remodeling in the CNS revealed by in vivo imaging. *Curr. Biol.* **28**, 549–559.e3 (2018). doi:10.1016/j.cub.2018.01.017
171. Yeung, M. S. Y. *et al.* Dynamics of oligodendrocyte generation and myelination in the human brain. *Cell* **159**, 766–74 (2014). doi:10.1016/j.cell.2014.10.011
172. Del Río-Hortega, P. Estudios sobre la neuroglia. La glia de escasas radiaciones oligodendroglia. *Bol Real Soc Espan Hist Nat* **21**, 63–92 (1921).
173. Del Río-Hortega, P. Tercera aportación al conocimiento morfológico e interpretación funcional de la oligodendroglia. *Mem Real Soc Espan Hist Nat* **14**, 40–122 (1928).
174. Freeman, M. R. & Rowitch, D. H. Evolving concepts of gliogenesis: a look way back and ahead to the next 25 years. *Neuron* **80**, 613–23 (2013). doi:10.1016/j.neuron.2013.10.034
175. van Bruggen, D., Agirre, E. & Castelo-Branco, G. Single-cell transcriptomic analysis of oligodendrocyte lineage cells. *Curr. Opin. Neurobiol.* **47**, 168–175 (2017). doi:10.1016/j.conb.2017.10.005
176. Zeisel, A. *et al.* Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* **347**, 1138–1142 (2015). doi:10.1126/science.aaa1934
177. Tomassy, G. S., Dershowitz, L. B. & Arlotta, P. Diversity matters: A revised guide to myelination. *Trends Cell Biol.* **26**, 135–147 (2016). doi:10.1016/j.tcb.2015.09.002
178. Brody, B. A., Kinney, H. C., Kloman, A. S. & Gilles, F. H. Sequence of central nervous system myelination in human infancy. I. An autopsy study of myelination. *J. Neuropathol. Exp. Neurol.* **46**, 283–301 (1987). doi:10.1097/00005072-198705000-00005
179. Kinney, H. C., Ann brody, B., Kloman, A. S. & Gilles, F. H. Sequence of central nervous system myelination in human infancy. II. patterns of myelination in autopsied infants. *J. Neuropathol. Exp. Neurol.* **47**, 217–234 (1988). doi:10.1097/00005072-198805000-00003
180. Lee, Y. *et al.* Oligodendroglia metabolically support axons and contribute to neurodegeneration. *Nature* **487**, 443–8 (2012). doi:10.1038/nature11314
181. Chong, S. Y. C. *et al.* Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. *Proc. Natl. Acad. Sci.* **109**, 1299–1304 (2012). doi:10.1073/pnas.1113540109
182. Krasnow, A. M., Ford, M. C., Valdivia, L. E., Wilson, S. W. & Attwell, D. Regulation of developing myelin sheath elongation by oligodendrocyte calcium transients in vivo. *Nat. Neurosci.* **21**, 24–28 (2018). doi:10.1038/s41593-017-0031-y
183. Bakiri, Y., Káradóttir, R. T., Cossell, L. & Attwell, D. Morphological and electrical properties of oligodendrocytes in the white matter of the corpus callosum and cerebellum. *J. Physiol.* **589**, 559–573 (2011). doi:10.1113/jphysiol.2010.201376
184. Weruaga-Prieto, E., Eggl, P. & Celio, M. R. Topographic variations in rat brain oligodendrocyte morphology elucidated by injection of Lucifer Yellow in fixed tissue slices. *J. Neurocytol.* **25**, 19–31 (1996). doi:10.1007/BF02284783
185. Matthews, M. A. & Duncan, D. A quantitative study of morphological changes accompanying the initiation and progress of myelin production in the dorsal funiculus of the rat spinal cord. *J. Comp. Neurol.* **142**, 1–22 (1971). doi:10.1002/cne.901420102
186. Murray, J. A. & Blakemore, W. F. The relationship between internodal length and fibre diameter in the spinal cord of the cat. *J. Neurol. Sci.* **45**, 29–41 (1980). doi:10.1016/S0022-510X(80)80004-9
187. Hildebrand, C., Remahl, S., Persson, H. & Bjartmar, C. Myelinated nerve fibres in the CNS. *Prog. Neurobiol.* **40**, 319–84 (1993). doi:10.1016/0301-0082(93)90015-k
188. Butt, A. M., Colquhoun, K., Tutton, M. & Berry, M. Three-dimensional morphology of astrocytes and oligodendrocytes in the intact mouse optic nerve. *J. Neurocytol.* **23**, 469–485 (1994). doi:10.1007/BF0184071
189. Bechler, M. E., Byrne, L. & French-Constant, C. CNS myelin sheath lengths are an intrinsic property of oligodendrocytes. *Curr. Biol.* **25**, 2411–2416 (2015). doi:10.1016/j.cub.2015.07.056
190. Dangata, Y. Y. & Kaufman, M. H. Myelinogenesis in the optic nerve of (C57BL x CBA) F1 hybrid mice: A morphometric analysis. *Eur. J. Morphol.* **35**, 3–17 (1997). doi:10.1076/ejom.35.1.3.13057
191. Sturrock, R. R. Myelination of the mouse corpus callosum. *Neuropathol. Appl. Neurobiol.* **6**, 415–420 (1980). doi:10.1111/j.1365-2990.1980.tb00219.x
192. Fuster, J. M. Frontal lobe and cognitive development. *Journal of Neurocytology* **31**, 373–385 (2002). doi:10.1023/A:1024190429920
193. Giedd, J. N. & Rapoport, J. L. Structural MRI of pediatric brain development: What have we learned and where are we going? *Neuron* **67**, 728–734 (2010). doi:10.1016/j.neuron.2010.08.040
194. Walhovd, K. B., Johansen-Berg, H. & Káradóttir, R. T. Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies. *Neuroscience* **276**, 2–13 (2014). doi:10.1016/j.neuroscience.2014.06.058
195. O'Brien, J. S. & Sampson, E. L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. *J. Lipid Res.* **6**, 537–44 (1965).
196. Morell, P. & Quarles, R. H. Characteristic composition of myelin. in *Basic Neurochemistry: Molecular, Cellular and Medical Aspects* (Lippincott-Raven, 1999).
197. Trotter, J. L., Wegescheide, C. L. & Garvey, W. F. Regional studies of myelin proteins in human brain and spinal cord. *Neurochem. Res.* **9**, 133–46 (1984). doi:10.1007/BF00967665

198. Berlet, H. H. & Volk, B. Studies of human myelin proteins during old age. *Mech. Ageing Dev.* **14**, 211–222 (1980). doi:10.1016/0047-6374(80)90121-9
199. Wiggins, R. C. *et al.* Effects of aging and alcohol on the biochemical composition of histologically normal human brain. *Metab. Brain Dis.* **3**, 67–80 (1988). doi:10.1007/bf01001354
200. Roher, A. E. *et al.* Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. *Biochemistry* **41**, 11080–90 (2002). doi:10.1021/bi026173d
201. Sloane, J. A., Hinman, J. D., Lubonia, M., Hollander, W. & Abraham, C. R. Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey. *J. Neurochem.* **84**, 157–68 (2003). doi:10.1046/j.1471-4159.2003.01541.x
202. Oberheim, N. A., Goldman, S. A. & Nedergaard, M. Heterogeneity of astrocytic form and function. in *Methods in Molecular Biology* **814**, 23–45 (2012). doi:10.1007/978-1-61779-452-0_3
203. Kölliker, A. *Handbuch der Gewebelehre des Menschen.* (W. Engelmann, 1889).
204. Andriezen, W. L. The neuroglia elements in the human brain. *Br. Med. J.* **2**, 227–30 (1893). doi:10.1136/bmj.2.1700.227
205. Matyash, V. & Kettenmann, H. Heterogeneity in astrocyte morphology and physiology. *Brain Res. Rev.* **63**, 2–10 (2010). doi:10.1016/j.brainresrev.2009.12.001
206. Macnab, L. T. & Pow, D. V. Expression of the exon 9-skipping form of EAAT2 in astrocytes of rats. *Neuroscience* **150**, 705–11 (2007). doi:10.1016/j.neuroscience.2007.09.049
207. Butovsky, O., Martone, M. E., Jones, Y. Z. & Emery, B. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J. Neurosci.* **22**, 183–192 (2002). doi:10.1523/jneurosci.22-01-00183.2002
208. Ogata, K. & Kosaka, T. Structural and quantitative analysis of astrocytes in the mouse hippocampus. *Neuroscience* **113**, 221–233 (2002). doi:10.1016/S0306-4522(02)00041-6
209. Oberheim, N. A. *et al.* Loss of astrocytic domain organization in the epileptic brain. *J. Neurosci.* **28**, 3264–3276 (2008). doi:10.1523/JNEUROSCI.4980-07.2008
210. Oberheim, N. A. *et al.* Uniquely hominid features of adult human astrocytes. *J. Neurosci.* **29**, 3276–3287 (2009). doi:10.1523/JNEUROSCI.4707-08.2009
211. Han, X. *et al.* Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. *Cell Stem Cell* **12**, 342–353 (2013). doi:10.1016/j.stem.2012.12.015
212. Borowsky, I. W. & Collins, R. C. Metabolic anatomy of brain: A comparison of regional capillary density, glucose metabolism, and enzyme activities. *J. Comp. Neurol.* **288**, 401–413 (1989). doi:10.1002/cne.902880304
213. Murugesan, N., Demarest, T. G., Madri, J. A. & Pachter, J. S. Brain regional angiogenic potential at the neurovascular unit during normal aging. *Neurobiol. Aging* **33**, 1004.e1–1004.e16 (2012). doi:10.1016/j.neurobiolaging.2011.09.022
214. Varatharaj, A. *et al.* Blood–brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study. *J. Physiol.* **597**, 699–709 (2019). doi:10.1113/JP276887
215. Dutta, D. J. *et al.* Regulation of myelin structure and conduction velocity by perinodal astrocytes. *Proc. Natl. Acad. Sci.* **115**, 11832–11837 (2018). doi:10.1073/pnas.1811013115
216. Ramon y Cajal, S. Un nuevo proceder para la impregnacion de la neuroglia. *Bol. Soc. Esp. Biol.* **2**, 104–108 (1913).
217. Emsley, J. G. & Macklis, J. D. Astroglial heterogeneity closely reflects the neuronal-defined anatomy of the adult murine CNS. *Neuron Glia Biol.* **2**, 175–186 (2006). doi:10.1017/S1740925X06000202
218. Oberheim, N. A., Wang, X., Goldman, S. A. & Nedergaard, M. Astrocytic complexity distinguishes the human brain. *Trends Neurosci.* **29**, 547–53 (2006). doi:10.1016/j.tins.2006.08.004
219. John Lin, C.-C. *et al.* Identification of diverse astrocyte populations and their malignant analogs. *Nat. Neurosci.* **20**, 396–405 (2017). doi:10.1038/nn.4493
220. Nagy, J. ., Patel, D., Ochalski, P. A. . & Stelmack, G. . Connexin30 in rodent, cat and human brain: selective expression in gray matter astrocytes, co-localization with connexin43 at gap junctions and late developmental appearance. *Neuroscience* **88**, 447–468 (1999). doi:10.1016/S0306-4522(98)00191-2
221. Rouach, N. *et al.* Gap junctions and connexin expression in the normal and pathological central nervous system. *Biology of the Cell* **94**, 457–475 (2002). doi:10.1016/S0248-4900(02)00016-3
222. Haas, B. *et al.* Activity-dependent ATP-waves in the mouse neocortex are independent from astrocytic calcium waves. *Cereb. Cortex* **16**, 237–46 (2006). doi:10.1093/cercor/bhi101
223. Lee, S. H., Kim, W. T., Cornell-Bell, A. H. & Sontheimer, H. Astrocytes exhibit regional specificity in gap-junction coupling. *Glia* **11**, 315–325 (1994). doi:10.1002/glia.440110404
224. Menichella, D. M., Goodenough, D. A., Sirkowski, E., Scherer, S. S. & Paul, D. L. Connexins are critical for normal myelination in the CNS. *J. Neurosci.* **23**, 5963–5973 (2003). doi:10.1523/jneurosci.23-13-05963.2003
225. Butt, A. M. & Ransom, B. R. Morphology of astrocytes and oligodendrocytes during development in the intact rat optic nerve. *J. Comp. Neurol.* **338**, 141–158 (1993). doi:10.1002/cne.903380110
226. Sutor, B., Schmolke, C., Teubner, B., Schirmer, C. & Willecke, K. Myelination defects and neuronal hyperexcitability in the neocortex of connexin 32-deficient mice. *Cereb. Cortex* **10**, 684–697 (2000). doi:10.1093/cercor/10.7.684
227. Menichella, D. M. *et al.* Genetic and physiological evidence that oligodendrocyte gap junctions contribute to spatial buffering of potassium released during neuronal activity. *J. Neurosci.* **26**, 10984–10991 (2006). doi:10.1523/JNEUROSCI.0304-06.2006
228. Odermatt, B. *et al.* Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS. *J. Neurosci.* **23**, 4549–4559 (2003). doi:10.1523/jneurosci.23-11-04549.2003
229. Neusch, C., Rozengurt, N., Jacobs, R. E., Lester, H. A. & Kofuji, P. Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination. *J. Neurosci.* **21**, 5429–5438 (2001). doi:10.1523/jneurosci.21-15-05429.2001
230. Djukic, B., Casper, K. B., Philpot, B. D., Chin, L. S. & McCarthy, K. D. Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. *J. Neurosci.* **27**, 11354–11365 (2007). doi:10.1523/JNEUROSCI.0723-07.2007

231. Orthmann-Murphy, J. L., Freidin, M., Fischer, E., Scherer, S. S. & Abrams, C. K. Two distinct heterotypic channels mediate gap junction coupling between astrocyte and oligodendrocyte connexins. *J. Neurosci.* **27**, 13949–13957 (2007). doi:10.1523/JNEUROSCI.3395-07.2007
232. Tress, O. *et al.* Panglial gap junctional communication is essential for maintenance of myelin in the CNS. *J. Neurosci.* **32**, 7499–7518 (2012). doi:10.1523/JNEUROSCI.0392-12.2012
233. Lutz, S. E. *et al.* Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating phenotype and hippocampal CA₁ vacuolation. *J. Neurosci.* **29**, 7743–7752 (2009). doi:10.1523/JNEUROSCI.0341-09.2009
234. Pamphlett, R. & Kum Jew, S. Inorganic mercury in human astrocytes, oligodendrocytes, corticomotoneurons and the locus ceruleus: implications for multiple sclerosis, neurodegenerative disorders and gliomas. *BioMetals* **31**, 807–819 (2018). doi:10.1007/s10534-018-0124-4
235. Nyamoya, S. *et al.* G-protein-coupled receptor Gpr17 expression in two multiple sclerosis remyelination models. *Mol. Neurobiol.* **56**, 1109–1123 (2019). doi:10.1007/s12035-018-1146-1
236. Baxi, E. G. *et al.* Lineage tracing reveals dynamic changes in oligodendrocyte precursor cells following cuprizone-induced demyelination. *Glia* **65**, 2087–2098 (2017). doi:10.1002/glia.23229
237. Gudi, V., Gingele, S., Skripuletz, T. & Stangel, M. Glial response during cuprizone-induced demyelination and remyelination in the CNS: lessons learned. *Front. Cell. Neurosci.* **8**, 73 (2014). doi:10.3389/fncel.2014.00073
238. Jurevics, H. *et al.* Alterations in metabolism and gene expression in brain regions during cuprizone-induced demyelination and remyelination. *J. Neurochem.* **82**, 126–136 (2002). doi:10.1046/j.1471-4159.2002.00954.x
239. Crawford, A. H., Tripathi, R. B., Richardson, W. D. & Franklin, R. J. M. Developmental origin of oligodendrocyte lineage cells determines response to demyelination and susceptibility to age-associated functional decline. *Cell Rep.* **15**, 761–773 (2016). doi:10.1016/j.celrep.2016.03.069
240. Coppelino, G. T. *et al.* Differential local tissue permissiveness influences the final fate of GPR17-expressing oligodendrocyte precursors in two distinct models of demyelination. *Glia* **66**, 1118–1130 (2018). doi:10.1002/glia.23305
241. Lecca, D. *et al.* The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. *PLoS One* **3**, e3579 (2008). doi:10.1371/journal.pone.0003579
242. Reynolds, R. *et al.* The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. *Journal of Neurocytology* **31**, 523–536 (2002). doi:10.1023/A:1025747832215
243. Alonso, G. NG2 proteoglycan-expressing cells of the adult rat brain: possible involvement in the formation of glial scar astrocytes following stab wound. *Glia* **49**, 318–38 (2005). doi:10.1002/glia.20121
244. Gudi, V. *et al.* Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. *PLoS One* **6**, e22623 (2011). doi:10.1371/journal.pone.0022623
245. Miyamoto, N. *et al.* Astrocytes promote oligodendrogenesis after white matter damage via brain-derived neurotrophic factor. *J. Neurosci.* **35**, 14002–14008 (2015). doi:10.1523/JNEUROSCI.1592-15.2015
246. Barres, B. A. *et al.* Ciliary neurotrophic factor enhances the rate of oligodendrocyte generation. *Mol. Cell. Neurosci.* **8**, 146–156 (1996). doi:10.1006/mcne.1996.0053
247. Yan, H. & Rivkees, S. A. Hepatocyte growth factor stimulates the proliferation and migration of oligodendrocyte precursor cells. *J. Neurosci. Res.* **69**, 597–606 (2002). doi:10.1002/jnr.10323
248. Bansal, R. Fibroblast growth factors and their receptors in oligodendrocyte development: implications for demyelination and remyelination. *Dev. Neurosci.* **24**, 35–46 (2002). doi:10.1159/000064944
249. Winter, C. G., Saotome, Y., Levison, S. W. & Hirsh, D. A role for ciliary neurotrophic factor as an inducer of reactive gliosis, the glial response to central nervous system injury. *Proc. Natl. Acad. Sci.* **92**, 5865–5869 (1995). doi:10.1073/pnas.92.13.5865
250. Saha, R. N., Liu, X. & Pahan, K. Up-regulation of BDNF in astrocytes by TNF- α : a case for the neuroprotective role of cytokine. *J. Neuroimmune Pharmacol.* **1**, 212–22 (2006). doi:10.1007/s11481-006-9020-8
251. Yamada, T. *et al.* White matter astrocytes produce hepatocyte growth factor activator inhibitor in human brain tissues. *Exp. Neurol.* **153**, 60–64 (1998). doi:10.1006/exnr.1998.6874
252. Kuzis, K., Reed, S., Cherry, N. J., Woodward, W. R. & Eckenstein, F. P. Developmental time course of acidic and basic fibroblast growth factors' expression in distinct cellular populations of the rat central nervous system. *J. Comp. Neurol.* **358**, 142–53 (1995). doi:10.1002/cne.903580109
253. Skripuletz, T. *et al.* Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. *Brain* **136**, 147–167 (2013). doi:10.1093/brain/aws262
254. Hibbits, N., Yoshino, J., Le, T. Q. & Armstrong, R. C. Astroglial response during acute and chronic cuprizone demyelination and implications for remyelination. *ASN Neuro* **4**, AN20120062 (2012). doi:10.1042/AN20120062
255. Buschmann, J. P. *et al.* Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. *J. Mol. Neurosci.* **48**, 66–76 (2012). doi:10.1007/s12031-012-9773-x
256. Bsibsi, M. *et al.* Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. *Glia* **53**, 688–695 (2006). doi:10.1002/glia.20328
257. Liddelow, S. A. *et al.* Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* **541**, 481–487 (2017). doi:10.1038/nature21029
258. Tarassishin, L., Suh, H.-S. & Lee, S. C. LPS and IL-1 differentially activate mouse and human astrocytes: Role of CD14. *Glia* **62**, 999–1013 (2014). doi:10.1002/glia.22657
259. Nair, A., Frederick, T. J. & Miller, S. D. Astrocytes in multiple sclerosis: A product of their environment. *Cell. Mol. Life Sci.* **65**, 2702–20 (2008). doi:10.1007/s00018-008-8059-5
260. Kipp, M., Clarner, T., Dang, J., Copray, S. & Beyer, C. The cuprizone animal model: New insights into an old story. *Acta Neuropathologica* **118**, 723–736 (2009). doi:10.1007/s00401-009-0591-3
261. Janssen, K., Rickert, M., Clarner, T., Beyer, C. & Kipp, M. Absence of CCL2 and CCL3 ameliorates central nervous system grey matter but not white matter demyelination in the presence of an intact blood–brain barrier. *Mol. Neurobiol.* **53**, 1551–1564 (2016). doi:10.1007/s12035-015-9113-6
262. Anderson, M. A., Ao, Y. & Sofroniew, M. V. Heterogeneity of reactive astrocytes. *Neurosci. Lett.* **565**, 23–29 (2014). doi:10.1016/j.neulet.2013.12.030

263. Krasowska-Zoladek, A., Banaszewska, M., Kraszpulski, M. & Konat, G. W. Kinetics of inflammatory response of astrocytes induced by TLR 3 and TLR4 ligation. *J. Neurosci. Res.* **85**, 205–12 (2007). doi:10.1002/jnr.21088
264. Sofroniew, M. V. Molecular dissection of reactive astrogliosis and glial scar formation. *Trends Neurosci.* **32**, 638–647 (2009). doi:10.1016/j.tins.2009.08.002
265. Sofroniew, M. V. & Vinters, H. V. Astrocytes: Biology and pathology. *Acta Neuropathol.* **119**, 7–35 (2010). doi:10.1007/s00401-009-0619-8
266. Kiray, H., Lindsay, S. L., Hosseinzadeh, S. & Barnett, S. C. The multifaceted role of astrocytes in regulating myelination. *Exp. Neurol.* **283**, 541–9 (2016). doi:10.1016/j.expneurol.2016.03.009
267. Kramann, N. *et al.* Glial fibrillary acidic protein expression alters astrocytic chemokine release and protects mice from cuprizone-induced demyelination. *Glia* **67**, 1308–1319 (2019). doi:10.1002/glia.23605
268. Urbanski, M. M., Brendel, M. B. & Melendez-Vasquez, C. V. Acute and chronic demyelinated CNS lesions exhibit opposite elastic properties. *Sci. Rep.* **9**, 999 (2019). doi:10.1038/s41598-018-37745-7
269. Stoffels, J. M. J. *et al.* Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. *Brain* **136**, 116–131 (2013). doi:10.1093/brain/aw331
270. Espitia Pinzón, N. *et al.* Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter. *PLoS One* **9**, e100574 (2014). doi:10.1371/journal.pone.0100574
271. Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S. & Yong, V. W. Pathophysiology of the brain extracellular matrix: A new target for remyelination. *Nature Reviews Neuroscience* **14**, 722–729 (2013). doi:10.1038/nrn3550
272. Jong, J. M., Wang, P., Oomkens, M. & Baron, W. Remodeling of the interstitial extracellular matrix in white matter multiple sclerosis lesions: Implications for remyelination (failure). *J. Neurosci. Res.* **98**, 1370–1397 (2020). doi:10.1002/jnr.24582
273. Lafrenaye, A. D. & Fuss, B. Focal adhesion kinase can play unique and opposing roles in regulating the morphology of differentiating oligodendrocytes. *J. Neurochem.* **115**, 269–82 (2010). doi:10.1111/j.1471-4159.2010.06926.x
274. Baron, W., Shattil, S. J. & ffrench-Constant, C. The oligodendrocyte precursor mitogen PDGF stimulates proliferation by activation of $\alpha v \beta 3$ integrins. *EMBO J.* **21**, 1957–1966 (2002). doi:10.1093/emboj/21.8.1957
275. Stoffels, J. M. J., Zhao, C. & Baron, W. Fibronectin in tissue regeneration: Timely disassembly of the scaffold is necessary to complete the build. *Cell. Mol. Life Sci.* **70**, 4243–4253 (2013). doi:10.1007/s00018-013-1350-0
276. Frost, E. E., Kiernan, B. W., Faissner, A. & ffrench-Constant, C. Regulation of oligodendrocyte precursor migration by extracellular matrix: Evidence for substrate-specific inhibition of migration by tenascin-C? *Dev. Neurosci.* **18**, 266–273 (1996). doi:10.1159/00011416
277. Tripathi, A., Parikh, Z. S., Vora, P., Frost, E. E. & Pillai, P. P. pERK1/2 peripheral recruitment and filopodia protrusion augment oligodendrocyte progenitor cell migration: Combined effects of PDGF-A and fibronectin. *Cell. Mol. Neurobiol.* **37**, 183–194 (2017). doi:10.1007/s10571-016-0359-y
278. Baron, W. *et al.* Sulfatide-mediated control of extracellular matrix-dependent oligodendrocyte maturation. *Glia* **62**, 927–942 (2014). doi:10.1002/glia.22650
279. Buttery, P. C. & ffrench-Constant, C. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. *Mol. Cell. Neurosci.* **14**, 199–212 (1999). doi:10.1006/mcne.1999.0781
280. Maier, O. *et al.* Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? *Mol. Cell. Neurosci.* **28**, 390–401 (2005). doi:10.1016/j.mcn.2004.09.012
281. Šišková, Z., Baron, W., de Vries, H. & Hoekstra, D. Fibronectin impedes “myelin” sheet-directed flow in oligodendrocytes: A role for a beta 1 integrin-mediated PKC signaling pathway in vesicular trafficking. *Mol. Cell. Neurosci.* **33**, 150–159 (2006). doi:10.1016/j.mcn.2006.07.001
282. Lau, L. W. *et al.* Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. *Ann. Neurol.* **72**, 419–432 (2012). doi:10.1002/ana.23599
283. Keough, M. B. *et al.* An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. *Nat. Commun.* **7**, 11312 (2016). doi:10.1038/ncomms11312
284. Pendleton, J. C. *et al.* Chondroitin sulfate proteoglycans inhibit oligodendrocyte myelination through PTP σ . *Exp. Neurol.* **247**, 113–121 (2013). doi:10.1016/j.expneurol.2013.04.003
285. Siebert, J. R. & Osterhout, D. J. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. *J. Neurochem.* **119**, 176–88 (2011). doi:10.1111/j.1471-4159.2011.07370.x
286. Leipzig, N. D. & Shoichet, M. S. The effect of substrate stiffness on adult neural stem cell behavior. *Biomaterials* **30**, 6867–6878 (2009). doi:10.1016/j.biomaterials.2009.09.002
287. Budday, S. *et al.* Mechanical properties of gray and white matter brain tissue by indentation. *J. Mech. Behav. Biomed. Mater.* **46**, 318–330 (2015). doi:10.1016/j.jmbmb.2015.02.024
288. Škuljec, J. *et al.* Matrix metalloproteinases and their tissue inhibitors in Cuprizone-induced demyelination and remyelination of brain white and gray matter. *J. Neuropathol. Exp. Neurol.* **70**, 758–769 (2011). doi:10.1097/NEN.0b013e3182294fad
289. Veluthakal, R., Arora, D. K., Goalstone, M. L., Kowluru, R. A. & Kowluru, A. Metabolic stress induces caspase-3 mediated degradation and inactivation of farnesyl and geranylgeranyl transferase activities in pancreatic β -cells. *Cell. Physiol. Biochem.* **39**, 2110–2120 (2016). doi:10.1159/000447907
290. Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology. *Nat. Rev. Endocrinol.* **13**, 710–730 (2017). doi:10.1038/nrendo.2017.91
291. Camargo, N. *et al.* High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. *FASEB J.* **26**, 4302–15 (2012). doi:10.1096/fj.12-205807
292. Lindholm, M. W. & Nilsson, J. Simvastatin stimulates macrophage interleukin-1 β secretion through an isoprenylation-dependent mechanism. *Vascul. Pharmacol.* **46**, 91–96 (2007). doi:10.1016/j.vph.2006.07.001
293. McCarty, M. F. Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. *Med. Hypotheses* **60**, 634–9 (2003). doi:10.1016/s0306-9877(02)00232-3

294. Bramow, S. *et al.* Demyelination versus remyelination in progressive multiple sclerosis. *Brain* **133**, 2983–98 (2010). doi:10.1093/brain/awq250
295. Goldschmidt, T., Antel, J. P., König, F. B., Brück, W. & Kuhlmann, T. Remyelination capacity of the MS brain decreases with disease chronicity. *Neurology* **72**, 1914–21 (2009). doi:10.1212/WNL.0b013e3181a8260a
296. Münzel, E. J., Jolanda Münzel, E. & Williams, A. Promoting remyelination in multiple sclerosis-recent advances. *Drugs* **73**, 2017–29 (2013). doi:10.1007/s40265-013-0146-8
297. Duncan, I. D., Marik, R. L., Broman, A. T. & Heidari, M. Thin myelin sheaths as the hallmark of remyelination persist over time and preserve axon function. *Proc. Natl. Acad. Sci.* **114**, E9685–E9691 (2017). doi:10.1073/pnas.1714183114
298. Prineas, J. W., Kwon, E. E., Cho, E. -S & Sharer, L. R. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. *Ann. N. Y. Acad. Sci.* **436**, 11–32 (1984). doi:10.1111/j.1749-6632.1984.tb14773.x
299. Duncan, I. D. *et al.* The adult oligodendrocyte can participate in remyelination. *Proc. Natl. Acad. Sci.* **115**, E11807–E11816 (2018). doi:10.1073/pnas.1808064115
300. Lucchinetti, C. F. *et al.* Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. *Ann. Neurol.* **47**, 707–717 (2000). doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
301. Henderson, A. P. D., Barnett, M. H., Parratt, J. D. E. & Prineas, J. W. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. *Ann. Neurol.* **66**, 739–753 (2009). doi:10.1002/ana.21800
302. Frischer, J. M. *et al.* Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. *Ann. Neurol.* **78**, 710–21 (2015). doi:10.1002/ana.24497
303. Haider, L. *et al.* The topography of demyelination and neurodegeneration in the multiple sclerosis brain. *Brain* **139**, 807–15 (2016). doi:10.1093/brain/awv398
304. Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D. & Mørk, S. J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. *J. Neuropathol. Exp. Neurol.* **62**, 723–732 (2003). doi:10.1093/jnen/62.7.723
305. Bø, L., Vedeler, C. A., Nyland, H., Trapp, B. D. & Mørk, S. J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. *Mult. Scler. J.* **9**, 323–331 (2003). doi:10.1191/1352458503ms9170a
306. van Horssen, J., Brink, B. P., de Vries, H. E., van der Valk, P. & Bø, L. The blood-brain barrier in cortical multiple sclerosis lesions. *J. Neuropathol. Exp. Neurol.* **66**, 321–328 (2007). doi:10.1097/nen.0b013e318040b2de
307. Voskuhl, R. R. *et al.* Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis. *Proc. Natl. Acad. Sci.* **116**, 10130–10139 (2019). doi:10.1073/pnas.1821306116
308. Kirby, L. *et al.* Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. *Nat. Commun.* **10**, 3887 (2019). doi:10.1038/s41467-019-11638-3
309. Park, C. *et al.* The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions. *Acta Neuropathol. Commun.* **7**, 130 (2019). doi:10.1186/s40478-019-0779-2
310. Itoh, N. *et al.* Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes. *Proc. Natl. Acad. Sci.* **115**, E302–E309 (2018). doi:10.1073/pnas.1716032115
311. Kuipers, H. F. *et al.* Phosphorylation of α B-crystallin supports reactive astrogliosis in demyelination. *Proc. Natl. Acad. Sci.* **114**, E1745–E1754 (2017). doi:10.1073/pnas.1621314114
312. Peferoen, L. A. N. *et al.* Small heat shock proteins are induced during multiple sclerosis lesion development in white but not grey matter. *Acta Neuropathol. Commun.* **3**, 87 (2015). doi:10.1186/s40478-015-0267-2
313. Gorter, R. P. *et al.* Heat shock proteins are differentially expressed in brain and spinal cord: implications for multiple sclerosis. *Clin. Exp. Immunol.* **194**, 137–152 (2018). doi:10.1111/cei.13186
314. Wheeler, M. A. *et al.* MAFG-driven astrocytes promote CNS inflammation. *Nature* **578**, (2020). doi:10.1038/s41586-020-1999-0
315. Brambilla, R. *et al.* Astrocytes play a key role in EAE pathophysiology by orchestrating in the CNS the inflammatory response of resident and peripheral immune cells and by suppressing remyelination. *Glia* **62**, 452–67 (2014). doi:10.1002/glia.22616
316. Ghatak, N. R. Occurrence of oligodendrocytes within astrocytes in demyelinating lesions. *J. Neuropathol. Exp. Neurol.* **51**, 40–46 (1992). doi:10.1097/00005072-199201000-00006
317. Sofroniew, M. V. Astrocyte barriers to neurotoxic inflammation. *Nat. Rev. Neurosci.* **16**, 249–263 (2015). doi:10.1038/nrn3898
318. Norton, W. T., Aquino, D. A., Hozumi, I., Chiu, F. C. & Brosnan, C. F. Quantitative aspects of reactive gliosis: a review. *Neurochem. Res.* **17**, 877–85 (1992). doi:10.1007/bf00993263
319. Sobel, R. A. & Ahmed, A. S. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. *J. Neuropathol. Exp. Neurol.* **60**, 1198–1207 (2001). doi:10.1093/jnen/60.12.1198
320. Kamermans, A., Planting, K. E., Jalink, K., van Horssen, J. & de Vries, H. E. Reactive astrocytes in multiple sclerosis impair neuronal outgrowth through TRPM7-mediated chondroitin sulfate proteoglycan production. *Glia* **67**, 68–77 (2019). doi:10.1002/glia.23526
321. Baror, R. *et al.* Transforming growth factor-beta renders ageing microglia inhibitory to oligodendrocyte generation by CNS progenitors. *Glia* **67**, 1374–1384 (2019). doi:10.1002/glia.23612
322. Sherman, L. S. *et al.* Hyaluronate-based extracellular matrix: Keeping glia in their place. *GLIA* **38**, 93–102 (2002). doi:10.1002/glia.10053
323. Back, S. A. *et al.* Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. *Nat. Med.* **11**, 966–972 (2005). doi:10.1038/nm1279
324. Sloane, J. A. *et al.* Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. *Proc. Natl. Acad. Sci.* **107**, 11555–60 (2010). doi:10.1073/pnas.1006496107
325. Zhao, C., Fancy, S. P. J., Franklin, R. J. M. & ffrench-Constant, C. Up-regulation of oligodendrocyte precursor cell α V integrin and its extracellular ligands during central nervous system remyelination. *J. Neurosci. Res.* **87**, 3447–3455 (2009). doi:10.1002/jnr.22231
326. Espitia Pinzón, N. *et al.* Astrocyte-derived tissue transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination. *Sci. Rep.* **7**, 40995 (2017). doi:10.1038/srep40995

327. Stoffels, J. M. J., Hoekstra, D., Franklin, R. J. M., Baron, W. & Zhao, C. The EIIIA domain from astrocyte-derived fibronectin mediates proliferation of oligodendrocyte progenitor cells following CNS demyelination. *Glia* **63**, 242–256 (2015). doi:10.1002/glia.22748
328. Wang, P. *et al.* MMP7 cleaves remyelination-impairing fibronectin aggregates and its expression is reduced in chronic multiple sclerosis lesions. *Glia* **66**, 1625–1643 (2018). doi:10.1002/glia.23328
329. Werkman, I. *et al.* TLR3 agonists induce fibronectin aggregation by activated astrocytes: a role of pro-inflammatory cytokines and fibronectin splice variants. *Sci. Rep.* **10**, 532 (2020). doi:10.1038/s41598-019-57069-4
330. Pyka-Fościk, G., Zemła, J., Lis, G. J., Litwin, J. A. & Lekka, M. Changes in spinal cord stiffness in the course of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. *Arch. Biochem. Biophys.* **680**, (2020). doi:10.1016/j.abb.2019.108221
331. Spassky, N. *et al.* Directional guidance of oligodendroglial migration by class 3 semaphorins and netrin-1. *J. Neurosci.* **22**, 5992–6004 (2002). doi:20026573
332. Syed, Y. A. *et al.* Inhibition of CNS remyelination by the presence of semaphorin 3A. *J. Neurosci.* **31**, 3719–3728 (2011). doi:10.1523/JNEUROSCI.4930-10.2011
333. Williams, A. *et al.* Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? *Brain* **130**, 2554–65 (2007). doi:10.1093/brain/awm202
334. Piaton, G. *et al.* Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. *Brain* **134**, 1156–67 (2011). doi:10.1093/brain/awr022
335. Markoullis, K. *et al.* Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter. *Acta Neuropathol.* **123**, 873–886 (2012). doi:10.1007/s00401-012-0978-4
336. Markoullis, K. *et al.* Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis gray matter. *J. Neuropathol. Exp. Neurol.* **73**, 865–879 (2014). doi:10.1097/NEN.000000000000106
337. Brand-Schieber, E. *et al.* Connexin43, the major gap junction protein of astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis. *J. Neurosci. Res.* **80**, 798–808 (2005). doi:10.1002/jnr.20474
338. Li, T. *et al.* Connexin 43 deletion in astrocytes promotes CNS remyelination by modulating local inflammation. *Glia* **68**, 23770 (2019). doi:10.1002/glia.23770
339. Parenti, R. *et al.* Dynamic expression of Cx47 in mouse brain development and in the cuprizone model of myelin plasticity. *Glia* **58**, 1594–1609 (2010). doi:10.1002/glia.21032
340. Xu, D., Liu, Z., Wang, S., Peng, Y. & Sun, X. Astrocytes regulate the expression of Sp1R3 on oligodendrocyte progenitor cells through Cx47 and promote their proliferation. *Biochem. Biophys. Res. Commun.* **490**, 670–675 (2017). doi:10.1016/j.bbrc.2017.06.099
341. Brana, C. *et al.* Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions. *Neuropathol. Appl. Neurobiol.* **40**, 564–578 (2014). doi:10.1111/nan.12048
342. Rothhammer, V. *et al.* Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation. *Proc. Natl. Acad. Sci.* **114**, 2012–2017 (2017). doi:10.1073/pnas.1615413114
343. Foster, C. A. *et al.* FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. *Brain Pathol.* **19**, 254–66 (2009). doi:10.1111/j.1750-3639.2008.00182.x
344. Verkhratsky, A. & Nedergaard, M. Physiology of astroglia. *Physiol. Rev.* **98**, 239–389 (2018). doi:10.1152/physrev.00042.2016
345. Farmer, W. T. & Murai, K. Resolving astrocyte heterogeneity in the CNS. *Front. Cell. Neurosci.* **11**, 300 (2017). doi:10.3389/fncel.2017.00300
346. Prins, M. *et al.* Pathological differences between white and grey matter multiple sclerosis lesions. *Ann. N. Y. Acad. Sci.* **1351**, 99–113 (2015). doi:10.1111/nyas.12841
347. Brink, B. P. *et al.* The pathology of multiple sclerosis is location-dependent: No significant complement activation is detected in purely cortical lesions. *J. Neuropathol. Exp. Neurol.* **64**, 147–155 (2005). doi:10.1093/jnen/64.2.147
348. van Wageningen, T. A. & van Dam, A.-M. Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes. *Mult. Scler. J.* **24**, 895–896 (2018). doi:10.1177/1352458517739139
349. Wergeland, S., Torkildsen, Ø., Myhr, K.-M., Mørk, S. J. & Bø, L. The cuprizone model: Regional heterogeneity of pathology. *Acta Pathol. Microbiol. Immunol. Scand.* **120**, 648–57 (2012). doi:10.1111/j.1600-0463.2012.02882.x
350. Clarner, T. *et al.* Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions. *Glia* **60**, 1468–1480 (2012). doi:10.1002/glia.22367
351. Franklin, R. J. M., Zhao, C. & Sim, F. J. Ageing and CNS remyelination. *Neuroreport* **13**, 923–8 (2002).
352. Irvine, K. A. & Blakemore, W. F. Remyelination protects axons from demyelination-associated axon degeneration. *Brain* **131**, 1464–1477 (2008). doi:10.1093/brain/awn080
353. Albert, M., Antel, J. P., Brück, W. & Stadelmann, C. Extensive cortical remyelination in patients with chronic multiple sclerosis. *Brain Pathol.* **17**, 129–138 (2007). doi:10.1111/j.1750-3639.2006.00043.x
354. Merkler, D. *et al.* Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. *Brain Pathol.* **16**, 117–123 (2006). doi:10.1111/j.1750-3639.2006.00004.x
355. Hart, A. D., Wyttenbach, A., Hugh Perry, V. & Teeling, J. L. Age related changes in microglial phenotype vary between CNS regions: Grey versus white matter differences. *Brain. Behav. Immun.* **26**, 754–765 (2012). doi:10.1016/j.bbi.2011.11.006
356. Sholl, D. a. Dendritic organization in the neurons of the visual and motor cortices of the cat. *J. Anat.* **87**, 387–406.1 (1953).
357. Langhammer, C. G. *et al.* Automated Sholl analysis of digitized neuronal morphology at multiple scales: Whole cell Sholl analysis versus Sholl analysis of arbor subregions. *Cytom. Part A* **77**, 1160–1168 (2010). doi:10.1002/cyto.a.20954
358. Ogata, T. *et al.* Hes1 functions downstream of growth factors to maintain oligodendrocyte lineage cells in the early progenitor stage. *Neuroscience* **176**, 132–141 (2011). doi:10.1016/j.neuroscience.2010.12.015
359. Liu, A. *et al.* A molecular insight of Hes5-dependent inhibition of myelin gene expression: Old partners and new players. *EMBO J.* **25**, 4833–4842 (2006). doi:10.1038/sj.emboj.7601352

360. Dugas, J. C., Tai, Y. C., Speed, T. P., Ngai, J. & Barres, B. A. Functional genomic analysis of oligodendrocyte differentiation. *J. Neurosci.* **26**, 10967–10983 (2006). doi:10.1523/JNEUROSCI.2572-06.2006
361. Havrda, M. C. *et al.* Id2 mediates oligodendrocyte precursor cell maturation arrest and is tumorigenic in a pdgfr-rich microenvironment. *Cancer Res.* **74**, 1822–1832 (2014). doi:10.1158/0008-5472.CAN-13-1839
362. Hammond, E. *et al.* The Wnt effector transcription factor 7-like 2 positively regulates oligodendrocyte differentiation in a manner independent of Wnt/ -Catenin signaling. *J. Neurosci.* **35**, 5007–5022 (2015). doi:10.1523/JNEUROSCI.4787-14.2015
363. Kim, D. *et al.* Homo-trimerization is essential for the transcription factor function of Myrf for oligodendrocyte differentiation. *Nucleic Acids Res.* **45**, 5112–5125 (2017). doi:10.1093/nar/gkx080
364. Cai, J. *et al.* Co-localization of Nkx6.2 and Nkx2.2 homeodomain proteins in differentiated myelinating oligodendrocytes. *Glia* **58**, 458–468 (2010). doi:10.1002/glia.20937
365. Cervera, P. *et al.* Immunohistological localization of the myelinating cell-specific receptor LPA1. *Glia* **38**, 126–136 (2002). doi:10.1002/glia.10054
366. Gard, A. L., Burrell, M. R., Pfeiffer, S. E., Rudge, J. S. & Williams, W. C. Astroglial control of oligodendrocyte survival mediated by PDGF and leukemia inhibitory factor-like protein. *Development* **121**, 2187–2197 (1995).
367. Schulz, K., Kroner, A. & David, S. Iron efflux from astrocytes plays a role in remyelination. *J. Neurosci.* **32**, 4841–4847 (2012). doi:10.1523/JNEUROSCI.5328-11.2012
368. Chew, L.-J., King, W. C., Kennedy, A. & Gallo, V. Interferon-gamma inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells. *Glia* **52**, 127–143 (2005). doi:10.1002/glia.20232
369. Molina-Holgado, E., Vela, J. M., Arévalo-Martín, Á. & Guaza, C. LPS/IFN- γ cytotoxicity in oligodendroglial cells: Role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. *Eur. J. Neurosci.* **13**, 493–502 (2001). doi:10.1046/j.0953-816X.2000.01412.x
370. Tanner, D. C., Cherry, J. D. & Mayer-Pröschel, M. Oligodendrocyte progenitors reversibly exit the cell cycle and give rise to astrocytes in response to interferon- γ . *J. Neurosci.* **31**, 6235–6246 (2011). doi:10.1016/j.biotechadv.2011.08.021.Secreted
371. Maier, O., Fischer, R., Agresti, C. & Pfizenmaier, K. TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. *Biochem. Biophys. Res. Commun.* **440**, 336–341 (2013). doi:10.1016/j.bbrc.2013.09.083
372. Bonora, M. *et al.* Tumor necrosis factor- α impairs oligodendroglial differentiation through a mitochondria-dependent process. *Cell Death Differ.* **21**, 1198–1208 (2014). doi:10.1038/cdd.2014.35
373. Khaibullin, T. *et al.* Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. *Front. Immunol.* **8**, 531 (2017). doi:10.3389/fimmu.2017.00531
374. Gao, X. *et al.* Interferon-gamma protects against cuprizone-induced demyelination. *Mol. Cell. Neurosci.* **16**, 338–349 (2000). doi:10.1006/mcne.2000.0883
375. Arnett, H. A. *et al.* TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. *Nat. Neurosci.* **4**, 116–22 (2001). doi:10.1038/nn738
376. Maña, P., Liñares, D., Fordham, S., Staykova, M. & Willenborg, D. Deleterious role of IFN γ in a toxic model of central nervous system demyelination. *Am. J. Pathol.* **168**, 1464–1473 (2006). doi:10.2353/ajpath.2006.050799
377. Selmaj, K., Raine, C. S., Cannella, B. & Brosnan, C. F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. *J. Clin. Invest.* **87**, 949–954 (1991). doi:10.1172/JCI115102
378. Martins, T. B. *et al.* Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. *Am. J. Clin. Pathol.* **136**, 696–704 (2011). doi:10.1309/AJCP7UBK8IBVMVNR
379. Vissoci Reiche, E. *et al.* Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. *Mol. Med. Rep.* **7**, 1010–20 (2013). doi:10.3892/mmr.2013.1256
380. Su, Z. *et al.* Reactive astrocytes inhibit the survival and differentiation of oligodendrocyte precursor cells by secreted TNF- α . *J. Neurotrauma* **28**, 1089–1100 (2011). doi:10.1089/neu.2010.1597
381. Eugster, H. Pietro *et al.* Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. *Eur. J. Immunol.* **29**, 626–632 (1999). doi:10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.0.CO;2-A
382. Iocca, H. A. *et al.* TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. *J. Neuroimmunol.* **194**, 97–106 (2008). doi:10.1016/j.jneuroim.2007.12.003
383. Akassoglou, K. *et al.* Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendroglial pathology. *Am. J. Pathol.* **153**, 801–813 (1998). doi:10.1016/S0002-9440(10)65622-2
384. Agresti, C., D'Urso, D. & Levi, G. Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. *Eur. J. Neurosci.* **8**, 1106–1116 (1996).
385. Bsibsi, M., Nomden, A., van Noort, J. M. & Baron, W. Toll-like receptors 2 and 3 agonists differentially affect oligodendrocyte survival, differentiation, and myelin membrane formation. *J. Neurosci. Res.* **90**, 388–98 (2012). doi:10.1002/jnr.22767
386. Ranscht, B., Clapshaw, P. A., Price, J., Noble, M. & Seifert, W. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. *Proc. Natl. Acad. Sci.* **79**, 2709–13 (1982). doi:10.1073/pnas.79.8.2709
387. Saito, M., Kitamura, H. & Sugiyama, K. The specificity of monoclonal antibody A2B5 to c-series gangliosides. *J. Neurochem.* **78**, 64–74 (2001). doi:10.1046/j.1471-4159.2001.00365.x
388. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012). doi:10.1038/nmeth.2019
389. Meijering, E. *et al.* Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. *Cytometry. A* **58**, 167–176 (2004). doi:10.1002/cyto.a.20022
390. Wearne, S. L. *et al.* New techniques for imaging, digitization and analysis of three-dimensional neural morphology on multiple scales. *Neuroscience* **136**, 661–680 (2005). doi:10.1016/j.neuroscience.2005.05.053

391. Ramakers, C., Ruijter, J. M., Deprez, R. H. L. & Moorman, A. F. . Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. *Neurosci. Lett.* **339**, 62–66 (2003). doi:10.1016/S0304-3940(02)01423-4
392. Ruijter, J. M. *et al.* Amplification efficiency: Linking baseline and bias in the analysis of quantitative PCR data. *Nucleic Acids Res.* **37**, (2009). doi:10.1093/nar/gkp045
393. Smith, K. J., Blakemore, W. F. & McDonald, W. I. Central remyelination restores secure conduction. *Nature* **280**, 395–396 (1979). doi:10.1038/280395a0
394. Liebetanz, D. & Merkler, D. Effects of commissural de- and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. *Exp. Neurol.* **202**, 217–224 (2006). doi:10.1016/j.expneurol.2006.05.032
395. Enuka, Y., Hanukoglu, I., Edelheit, O., Vaknine, H. & Hanukoglu, A. Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways. *Histochem. Cell Biol.* **137**, 339–353 (2012). doi:10.1007/s00418-011-0904-1
396. Del Bigio, M. R. Ependymal cells: Biology and pathology. *Acta Neuropathologica* **119**, 55–73 (2010). doi:10.1007/s00401-009-0624-y
397. Corbit, K. C. *et al.* Vertebrate Smoothed functions at the primary cilium. *Nature* **437**, 1018–1021 (2005). doi:10.1038/nature04117
398. Wheway, G. *et al.* Aberrant Wnt signalling and cellular over-proliferation in a novel mouse model of Meckel-Gruber syndrome. *Dev. Biol.* **377**, 55–66 (2013). doi:10.1016/j.ydbio.2013.02.015
399. Lin, F. *et al.* Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. *Proc. Natl. Acad. Sci.* **100**, 5286–5291 (2003). doi:10.1073/pnas.0836980100
400. Cano, D. A., Murcia, N. S., Pazour, G. J. & Hebrok, M. Orpk mouse model of polycystic kidney disease reveals essential role of primary cilia in pancreatic tissue organization. *Development* **131**, 3457–3467 (2004). doi:10.1242/dev.01189
401. Abdelhamed, Z. A. *et al.* Variable expressivity of ciliopathy neurological phenotypes that encompass Meckel - Gruber syndrome and Joubert syndrome is caused by complex de-regulated ciliogenesis, Shh and wnt signalling defects. *Hum. Mol. Genet.* **22**, 1358–1372 (2013). doi:10.1093/hmg/dd546
402. Wheway, G., Nazlamova, L. & Hancock, J. T. Signaling through the primary cilium. *Frontiers in Cell and Developmental Biology* **6**, (2018). doi:10.3389/fcell.2018.00008
403. Schneider, L. *et al.* PDGFR α signaling is regulated through the primary cilium in fibroblasts. *Curr. Biol.* **15**, 1861–1866 (2005). doi:10.1016/j.cub.2005.09.012
404. Martin, L. *et al.* Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia. *Hum. Mol. Genet.* **27**, 1–13 (2018). doi:10.1093/hmg/ddx374
405. Ezratty, E. J., Pasolli, H. A. & Fuchs, E. A Presenilin-2-ARF4 trafficking axis modulates Notch signaling during epidermal differentiation. *J. Cell Biol.* **214**, 89–101 (2016). doi:10.1083/jcb.201508082
406. Boehlke, C. *et al.* Primary cilia regulate mTORC1 activity and cell size through Lkb1. *Nat. Cell Biol.* **12**, 1115–1122 (2010). doi:10.1038/ncb2117
407. Gruchot, J. *et al.* The molecular basis for remyelination failure in multiple sclerosis. *Cells* **8**, (2019). doi:10.3390/cells8080825
408. Wheeler, N. A. & Fuss, B. Extracellular cues influencing oligodendrocyte differentiation and (re) myelination. *Experimental Neurology* **283**, 512–530 (2016). doi:10.1016/j.expneurol.2016.03.019
409. Sanchez, M. A. & Armstrong, R. C. Postnatal Sonic hedgehog (Shh) responsive cells give rise to oligodendrocyte lineage cells during myelination and in adulthood contribute to remyelination. *Exp. Neurol.* **299**, 122–136 (2018). doi:10.1016/j.expneurol.2017.10.010
410. Matsushima, G. K. & Morell, P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. in *Brain Pathology* **11**, 107–116 (International Society of Neuropathology, 2001). doi:10.1111/j.1750-3639.2001.tb00385.x
411. Pfeiffer, S. E., Warrington, A. E. & Bansal, R. The oligodendrocyte and its many cellular processes. *Trends Cell Biol.* **3**, 191–197 (1993). doi:10.1016/0962-8924(93)90213-K
412. Loges, N. T. *et al.* DNAL2 mutations cause primary ciliary dyskinesia with defects in the outer dynein arm. *Am. J. Hum. Genet.* **83**, 547–558 (2008). doi:10.1016/j.ajhg.2008.10.001
413. Horio, T. *et al.* The fission yeast γ -tubulin is essential for mitosis and is localized at microtubule organizing centres. *J. Cell Sci.* **99**, 693–700 (1991).
414. Pazour, G. J. *et al.* Chlamydomonas IFT88 and its mouse homologue, polycystic kidney disease gene Tg737, are required for assembly of cilia and flagella. *J. Cell Biol.* **151**, 709–718 (2000). doi:10.1083/jcb.151.3.709
415. Bögl, O., Wren, D., Barnett, S. C., Land, H. & Noble, M. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. *Proc. Natl. Acad. Sci.* **87**, 6368–6372 (1990). doi:10.1073/pnas.87.16.6368
416. Gerdes, J. *et al.* Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J. Immunol.* **133**, 1710–5 (1984).
417. Umberger, N. L. & Caspary, T. Ciliary transport regulates PDGF-AA/ α signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity. *Mol. Biol. Cell* **26**, 350–358 (2015). doi:10.1091/mbc.E14-05-0952
418. Zhu, D., Shi, S., Wang, H. & Liao, K. Growth arrest induces primary-cilium formation and sensitizes IGF-1-receptor signaling during differentiation induction of 3T3-L1 preadipocytes. *J. Cell Sci.* **122**, 2760–2768 (2009). doi:10.1242/jcs.046276
419. Langseth, A. J. *et al.* Wnts influence the timing and efficiency of oligodendrocyte precursor cell generation in the telencephalon. *J. Neurosci.* **30**, 13367–13372 (2010). doi:10.1523/JNEUROSCI.1934-10.2010
420. Feigenson, K., Reid, M., See, J., Crenshaw, E. B. & Grinspan, J. B. Wnt signaling is sufficient to perturb oligodendrocyte maturation. *Mol. Cell. Neurosci.* **42**, 255–265 (2009). doi:10.1016/j.mcn.2009.07.010
421. Dai, Z. M. *et al.* Stage-specific regulation of oligodendrocyte development by Wnt/ β -catenin signaling. *J. Neurosci.* **34**, 8467–8473 (2014). doi:10.1523/JNEUROSCI.0311-14.2014
422. Mengler, L. *et al.* Brain maturation of the adolescent rat cortex and striatum: Changes in volume and myelination. *Neuroimage* **84**, 35–44 (2014). doi:10.1016/j.neuroimage.2013.08.034

423. Gaesser, J. M. & Fyffe-Maricich, S. L. Intracellular signaling pathway regulation of myelination and remyelination in the CNS. *Experimental Neurology* **283**, 501–511 (2016). doi:10.1016/j.expneurol.2016.03.008
424. Huang, P. & Schier, A. F. Dampened Hedgehog signaling but normal Wnt signaling in zebrafish without cilia. *Development* **136**, 3089–3098 (2009). doi:10.1242/dev.041343
425. Kyun, M.-L. L. *et al.* Wnt3a stimulation promotes primary ciliogenesis through β -Catenin phosphorylation-induced reorganization of centriolar satellites. *Cell Rep.* **30**, 1447–1462.e5 (2020). doi:10.1016/j.celrep.2020.01.019
426. See, J. *et al.* Oligodendrocyte maturation is inhibited by bone morphogenetic protein. *Mol. Cell. Neurosci.* **26**, 481–492 (2004). doi:10.1016/j.mcn.2004.04.004
427. Syed, Y. A. *et al.* Inhibition of oligodendrocyte precursor cell differentiation by myelin-associated proteins. *Neurosurg. Focus* **24**, E5 (2008). doi:10.3171/FOC/2008/24/3-4/E4
428. Baer, A. S. *et al.* Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. *Brain* **132**, 465–481 (2009). doi:10.1093/brain/awn334
429. Wheeler, D., Bandaru, V. V. R., Calabresi, P. A., Nath, A. & Haughey, N. J. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. *Brain* **131**, 3092–3102 (2008). doi:10.1093/brain/awn190
430. Smith, M. E. Phagocytosis of myelin by microglia in vitro. *J. Neurosci. Res.* **35**, 480–487 (1993). doi:10.1002/jnr.490350504
431. Mosley, K. & Cuzner, M. L. Receptor-mediated phagocytosis of myelin by macrophages and microglia: Effect of opsonization and receptor blocking agents. *Neurochem. Res.* **21**, 481–487 (1996). doi:10.1007/BF02527713
432. Durafourt, B. A. *et al.* Comparison of polarization properties of human adult microglia and blood-derived macrophages. *Glia* **60**, 717–727 (2012). doi:10.1002/glia.22298
433. Grajchen, E., Hendriks, J. J. A. & Bogie, J. F. J. The physiology of foamy phagocytes in multiple sclerosis. *Acta Neuropathologica Communications* **6**, 124 (2018). doi:10.1186/s40478-018-0628-8
434. Bogie, J. F. J. *et al.* Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. *J. Exp. Med.* **217**, (2020). doi:10.1084/jem.20191660
435. Gopalakrishnan, G. *et al.* Lipidome and proteome map of myelin membranes. *J. Neurosci. Res.* **91**, 321–334 (2013). doi:10.1002/jnr.23157
436. Werkman, I. L., Lentferink, D. H. & Baron, W. Macrogial diversity: white and grey areas and relevance to remyelination. *Cellular and Molecular Life Sciences* (2020). doi:10.1007/s00018-020-03586-9
437. Syed, Y. A. *et al.* Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination. *Acta Neuropathol.* **131**, 281–298 (2016). doi:10.1007/s00401-015-1521-1
438. Zhang, Z. *et al.* Parenchymal accumulation of CD163+ macrophages/microglia in multiple sclerosis brains. *J. Neuroimmunol.* **237**, 73–79 (2011). doi:10.1016/j.jneuroim.2011.06.006
439. Kroner, A. *et al.* TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. *Neuron* **83**, 1098–1116 (2014). doi:10.1016/j.neuron.2014.07.027
440. Liu, Y. *et al.* Suppression of microglial inflammatory activity by myelin phagocytosis: Role of p47-PHOX-mediated generation of reactive oxygen species. *J. Neurosci.* **26**, 12904–12913 (2006). doi:10.1523/JNEUROSCI.2531-06.2006
441. van der Laan, L. J. W. *et al.* Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor- α and nitric oxide. *J. Neuroimmunol.* **70**, 145–152 (1996). doi:10.1016/S0165-5728(96)00110-5
442. van Zwam, M. *et al.* Myelin ingestion alters macrophage antigen-presenting function in vitro and in vivo. *J. Leukoc. Biol.* **90**, 123–132 (2011). doi:10.1189/jlb.1209813
443. Wang, X. *et al.* Macrophages in spinal cord injury: Phenotypic and functional change from exposure to myelin debris. *Glia* **63**, 635–651 (2015). doi:10.1002/glia.22774
444. Williams, K., Ulvestad, E., Waage, A., Antel, J. P. & McLaurin, J. Activation of adult human derived microglia by myelin phagocytosis in vitro. *J. Neurosci. Res.* **38**, 433–443 (1994). doi:10.1002/jnr.490380409
445. Sikkema, A. H. *et al.* Fibronectin aggregates promote features of a classically and alternatively activated phenotype in macrophages. *J. Neuroinflammation* **15**, (2018). doi:10.1186/s12974-018-1238-x
446. Hsieh, J. *et al.* IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. *J. Cell Biol.* **164**, 111–122 (2004). doi:10.1083/jcb.200308101
447. Spadaro, O. *et al.* IGF1 shapes macrophage activation in response to immunometabolic challenge. *Cell Rep.* **19**, 225–234 (2017). doi:10.1016/j.celrep.2017.03.046
448. Walter, H. J., Berry, M., Hill, D. J. & Logan, A. Spatial and temporal changes in the insulin-like growth factor (IGF) axis indicate autocrine/paracrine actions of IGF-I within wounds of the rat brain. *Endocrinology* **138**, 3024–3034 (1997). doi:10.1210/endo.138.7.5284
449. Burguillos, M. A. *et al.* Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. *Cell Rep.* **10**, 1626–1638 (2015). doi:10.1016/j.celrep.2015.02.012
450. Sato, S. & Hughes, R. C. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. *J. Biol. Chem.* **269**, 4424–4430 (1994).
451. Pasquini, L. A. *et al.* Galectin-3 drives oligodendrocyte differentiation to control myelin integrity and function. *Cell Death Differ.* **18**, 1746–1756 (2011). doi:10.1038/cdd.2011.40
452. Burton, M. D., Ryttych, J. L., Freund, G. G. & Johnson, R. W. Central inhibition of interleukin-6 trans-signaling during peripheral infection reduced neuroinflammation and sickness in aged mice. *Brain. Behav. Immun.* **30**, 66–72 (2013). doi:10.1016/j.bbi.2013.01.002
453. Manderson, A. P., Kay, J. G., Hammond, L. A., Brown, D. L. & Stow, J. L. Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNF α . *J. Cell Biol.* **178**, 57–69 (2007). doi:10.1083/jcb.200612131
454. Zhang, P., Chebath, J., Lonai, P. & Revel, M. Enhancement of oligodendrocyte differentiation from murine embryonic stem cells by an activator of gp130 signaling. *Stem Cells* **22**, 344–354 (2004). doi:10.1634/stemcells.22-3-344
455. Talbot, J. F. *et al.* CNTF promotes the survival and differentiation of adult spinal cord-derived oligodendrocyte precursor cells in vitro but fails to promote remyelination in vivo. *Exp. Neurol.* **204**, 485–489 (2007). doi:10.1016/j.expneurol.2006.12.013

456. Tanaka, T. *et al.* Microglia support ATF3-positive neurons following hypoglossal nerve axotomy. *Neurochem. Int.* **108**, 332–342 (2017). doi:10.1016/j.neuint.2017.05.007
457. Deverman, B. E. & Patterson, P. H. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. *J. Neurosci.* **32**, 2100–2109 (2012). doi:10.1523/JNEUROSCI.3803-11.2012
458. Nakanishi, M. *et al.* Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. *Eur. J. Neurosci.* **25**, 649–658 (2007). doi:10.1111/j.1460-9568.2007.05309.x
459. Glezer, I. & Rivest, S. Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites. *Brain, Behavior, and Immunity* **24**, 695–704 (2010). doi:10.1016/j.bbi.2010.01.005
460. Repovic, P. & Benveniste, E. N. Prostaglandin E₂ is a novel inducer of oncostatin-M expression in macrophages and microglia. *J. Neurosci.* **22**, 5334–5343 (2002). doi:10.1523/jneurosci.22-13-05334.2002
461. Sodhi, A., Shishodia, S. & Shrivastava, A. Cisplatin-stimulated murine bone marrow-derived macrophages secrete oncostatin M. *Immunol. Cell Biol.* **75**, 492–496 (1997). doi:10.1038/icb.1997.76
462. Rawji, K. S., Mishra, M. K. & Yong, V. W. Regenerative capacity of macrophages for remyelination. *Frontiers in Cell and Developmental Biology* **4**, 47 (2016). doi:10.3389/fcell.2016.00047
463. Baaklini, C. S., Rawji, K. S., Duncan, G. J., Ho, M. F. S. & Plemel, J. R. Central nervous system remyelination: Roles of glia and innate immune cells. *Frontiers in Molecular Neuroscience* **12**, 225 (2019). doi:10.3389/fnmol.2019.00225
464. Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. *J. Immunol.* **177**, 7303–7311 (2006). doi:10.4049/jimmunol.177.10.7303
465. Boltz-Nitulescu, G. *et al.* Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant. *J. Leukoc. Biol.* **41**, 83–91 (1987). doi:10.1002/jlb.41.1.83
466. Davis, B. K. Isolation, culture, and functional evaluation of bone marrow-derived macrophages. *Methods Mol. Biol.* **1031**, 27–35 (2013). doi:10.1007/978-1-62703-481-4_3
467. Norton, W. T. & Poduslo, S. E. Myelination in rat brain: Method of myelin isolation. *J. Neurochem.* **21**, 749–757 (1973). doi:10.1111/j.1471-4159.1973.tb07519.x
468. Sommer, I. & Schachner, M. Monoclonal antibodies (O₁ to O₄) to oligodendrocyte cell surfaces: An immunocytological study in the central nervous system. *Dev. Biol.* **83**, 311–327 (1981). doi:10.1016/0012-1606(81)90477-2
469. Rysman, E. *et al.* De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. *Cancer Res.* **70**, 8117–8126 (2010). doi:10.1158/0008-5472.CAN-09-3871
470. Liebisch, G., Lieser, B., Rathenberg, J., Drobnik, W. & Schmitz, G. High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* **1686**, 108–117 (2004). doi:10.1016/j.bbalip.2004.09.003
471. Plemel, J. R., Manesh, S. B., Sparling, J. S. & Tetzlaff, W. Myelin inhibits oligodendroglial maturation and regulates oligodendrocytic transcription factor expression. *Glia* **61**, 1471–1487 (2013). doi:10.1002/glia.22535
472. Robinson, S. & Miller, R. H. Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation. *Dev. Biol.* **216**, 359–368 (1999). doi:10.1006/dbio.1999.9466
473. Jeon, S.-B., Yoon, H. J., Park, S.-H., Kim, I.-H. & Park, E. J. Sulfatide, a major lipid component of myelin sheath, activates inflammatory responses as an endogenous stimulator in brain-resident immune cells. *J. Immunol.* **181**, 8077–8087 (2008). doi:10.4049/jimmunol.181.11.8077
474. Bachstetter, A. D., Webster, S. J., van Eldik, L. J. & Cambi, F. Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain. *J. Neuroinflammation* **10**, (2013). doi:10.1186/1742-2094-10-146
475. Tatar, C. L. *et al.* Increased Plp1 gene expression leads to massive microglial cell activation and inflammation throughout the brain. *ASN Neuro* **2**, 219–231 (2010). doi:10.1042/AN20100016
476. Ip, C. W. *et al.* Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. *J. Neurosci.* **26**, 8206–8216 (2006). doi:10.1523/JNEUROSCI.1921-06.2006
477. Grajchen, E. *et al.* CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation. *J. Neuroinflammation* **17**, (2020). doi:10.1186/s12974-020-01899-x
478. van der Poel, M. *et al.* Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes. *Nat. Commun.* **10**, (2019). doi:10.1038/s41467-019-08976-7
479. Grabert, K. *et al.* Microglial brain region-dependent diversity and selective regional sensitivities to aging. *Nat. Neurosci.* **19**, 504–516 (2016). doi:10.1038/nn.4222
480. Healy, L. M. *et al.* MerTK Is a Functional Regulator of Myelin Phagocytosis by Human Myeloid Cells. *J. Immunol.* **196**, 3375–3384 (2016). doi:10.4049/jimmunol.1502562
481. Yamasaki, R. *et al.* Differential roles of microglia and monocytes in the inflamed central nervous system. *J. Exp. Med.* **211**, 1533–1549 (2014). doi:10.1084/jem.20132477
482. Jäckle, K. *et al.* Molecular signature of slowly expanding lesions in progressive multiple sclerosis. *Brain* **143**, 2073–2088 (2020). doi:10.1093/brain/awaa158
483. Heß, K. *et al.* Lesion stage-dependent causes for impaired remyelination in MS. *Acta Neuropathol.* **140**, 359–375 (2020). doi:10.1007/s00401-020-02189-9
484. Vogel, D. Y. S. *et al.* Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. *J. Neuroinflammation* **10**, (2013). doi:10.1186/1742-2094-10-35
485. Cunha, M. I. *et al.* Pro-inflammatory activation following demyelination is required for myelin clearance and oligodendrogenesis. *J. Exp. Med.* **217**, (2020). doi:10.1084/jem.20191390
486. Sankowski, R. *et al.* Mapping microglia states in the human brain through the integration of high-dimensional techniques. *Nat. Neurosci.* **22**, 2098–2110 (2019). doi:10.1038/s41593-019-0532-y
487. Chari, D. M., Crang, A. J. & Blakemore, W. F. Decline in rate of colonization of oligodendrocyte progenitor cell (OPC)-depleted tissue by adult OPCs with age. *J. Neuropathol. Exp. Neurol.* **62**, 908–916 (2003). doi:10.1093/jnen/62.9.908

488. Ruckh, J. M. *et al.* Rejuvenation of regeneration in the aging central nervous system. *Cell Stem Cell* **10**, 96–103 (2012). doi:10.1016/j.stem.2011.11.019
489. Cantuti-Castelvetri, L. *et al.* Defective cholesterol clearance limits remyelination in the aged central nervous system. *Science* **359**, 684–688 (2018). doi:10.1126/science.aan4183
490. Zhao, C., Li, W. W. & Franklin, R. J. M. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. *Neurobiol. Aging* **27**, 1298–1307 (2006). doi:10.1016/j.neurobiolaging.2005.06.008
491. Roy, N. S. *et al.* Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter. *J. Neurosci.* **19**, 9986–9995 (1999). doi:10.1523/jneurosci.19-22-09986.1999
492. Nunes, M. C. *et al.* Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. *Nat. Med.* **9**, 439–447 (2003). doi:10.1038/nm837
493. Windrem, M. S. *et al.* Human glial progenitor cells effectively remyelinate the demyelinated adult brain. *Cell Rep.* **31**, 107658 (2020). doi:10.1016/j.celrep.2020.107658
494. Windrem, M. S. *et al.* Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. *J. Neurosci. Res.* **69**, 966–975 (2002). doi:10.1002/jnr.10397
495. Bolot, G. *et al.* A set of glycoproteins recognized by A2B5 antibody with major bands at 55 and 76 kDa is overexpressed in human head and neck squamous cell carcinomas. *Biochimie* **85**, 409–412 (2003). doi:10.1016/S0300-9084(03)00044-0
496. Inoko, E. *et al.* Developmental stage-dependent expression of an α 2,8-trisialic acid unit on glycoproteins in mouse brain. *Glycobiology* **20**, 916–928 (2010). doi:10.1093/glycob/cwq049
497. Raff, M. C., Miller, R. H. & Noble, M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. *Nature* **303**, 390–396 (1983). doi:10.1038/303390a0
498. Esmonde-White, C. *et al.* Distinct function-related molecular profile of adult human A2b5-positive pre-oligodendrocytes versus mature oligodendrocytes. *J. Neuropathol. Exp. Neurol.* **78**, 468–479 (2019). doi:10.1093/jnen/nlz026
499. Rao, M. S., Noble, M. & Mayer-Pröschel, M. A tripotential glial precursor cell is present in the developing spinal cord. *Proc. Natl. Acad. Sci.* **95**, 3996–4001 (1998). doi:10.1073/pnas.95.7.3996
500. Sim, F. J., Windrem, M. S. & Goldman, S. A. Fate determination of adult human glial progenitor cells. *Neuron Glia Biology* **5**, 45–55 (2009). doi:10.1017/S1740925X09990317
501. Sim, F. J. *et al.* Complementary patterns of gene expression by human oligodendrocyte progenitors and their environment predict determinants of progenitor maintenance and differentiation. *Ann. Neurol.* **59**, 763–779 (2006). doi:10.1002/ana.20812
502. Dietrich, J., Noble, M. & Mayer-Pröschel, M. Characterization of A2B5+ glial precursor cells from cryopreserved human fetal brain progenitor cells. *Glia* **40**, 65–77 (2002). doi:10.1002/glia.10116
503. Colin, C. *et al.* In vitro identification and functional characterization of glial precursor cells in human gliomas. *Neuropathol. Appl. Neurobiol.* **32**, 189–202 (2006). doi:10.1111/j.1365-2990.2006.00740.x
504. Baeza-Kallee, N. *et al.* Glycolipids recognized by A2B5 antibody promote proliferation, migration, and clonogenicity in glioblastoma cells. *Cancers (Basel)*. **11**, 1267 (2019). doi:10.3390/cancers11091267
505. McKenzie, A. T. *et al.* Brain cell type specific gene expression and co-expression network architectures. *Sci. Rep.* **8**, (2018). doi:10.1038/s41598-018-27293-5
506. Dong, M. *et al.* SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references. *Brief. Bioinform.* **2020**, 1–12 (2020). doi:10.1093/bib/bbz166
507. Ximerakis, M. *et al.* Single-cell transcriptomic profiling of the aging mouse brain. *Nat. Neurosci.* **22**, 1696–1708 (2019). doi:10.1038/s41593-019-0491-3
508. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014). doi:10.1186/gb-2014-15-2-r29
509. Petryniak, M. A., Potter, G. B., Rowitch, D. H. & Rubenstein, J. L. R. Dlx1 and Dlx2 control neuronal versus oligodendroglial cell fate acquisition in the developing forebrain. *Neuron* **55**, 417–433 (2007). doi:10.1016/j.neuron.2007.06.036
510. Mouton-Liger, F. *et al.* PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca2+/Calmodulin-Dependent kinase II- δ activation in mouse models of down syndrome. *J. Comp. Neurol.* **519**, 2779–2802 (2011). doi:10.1002/cne.22651
511. Zhu, L. *et al.* Microglia/monocytes with NG2 expression have no phagocytic function in the cortex after LPS focal injection into the rat brain. *Glia* **60**, 1417–1426 (2012). doi:10.1002/glia.22362
512. Zhu, L. *et al.* NG2 expression in microglial cells affects the expression of neurotrophic and proinflammatory factors by regulating FAK phosphorylation. *Sci. Rep.* **6**, (2016). doi:10.1038/srep27983
513. Ruffini, F., Arbour, N., Blain, M., Olivier, A. & Antel, J. P. Distinctive properties of human adult brain-derived myelin progenitor cells. *Am. J. Pathol.* **165**, 2167–2175 (2004). doi:10.1016/S0002-9440(10)63266-X
514. Yokoyama, A., Yang, L., Itoh, S., Mori, K. & Tanaka, J. Microglia, a potential source of neurons, astrocytes, and oligodendrocytes. *Glia* **45**, 96–104 (2004). doi:10.1002/glia.10306
515. Rakic, S. & Zecevic, N. Early oligodendrocyte progenitor cells in the human fetal telencephalon. *Glia* **41**, 117–127 (2003). doi:10.1002/glia.10140
516. de la Fuente, A. G. *et al.* Changes in the oligodendrocyte progenitor cell proteome with ageing. *Mol. Cell. Proteomics* **19**, 1281–1302 (2020). doi:10.1074/mcp.RA120.002102
517. Ellison, J. A. & de Vellis, J. Amoeboid microglia expressing GD3 ganglioside are concentrated in regions of oligodendrogenesis during development of the rat corpus callosum. *Glia* **14**, 123–132 (1995). doi:10.1002/glia.440140207
518. Andersson, L. M., Fredman, P., Lekman, A., Rosengren, L. & Gisslen, M. Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. *AIDS Res. Hum. Retroviruses* **14**, 1065–1069 (1998). doi:10.1089/aid.1998.14.1065
519. Simon, B. M., Malisan, F., Testi, R., Nicotera, P. & Leist, M. Disialoganglioside GD3 is released by microglia and induces oligodendrocyte apoptosis. *Cell Death Differ.* **9**, 758–767 (2002). doi:10.1038/sj.cdd.4401027

520. Segel, M. *et al.* Niche stiffness underlies the aging of central nervous system progenitor cells. *Nature* **573**, 130–134 (2019). doi:10.1038/s41586-019-1484-9
521. Lloyd, A. F. *et al.* Central nervous system regeneration is driven by microglia necroptosis and repopulation. *Nat. Neurosci.* **22**, 1046–1052 (2019). doi:10.1038/s41593-019-0418-z
522. Kundu, S. K., Pleatman, M. A., Redwine, W. A., Boyd, A. E. & Marcus, D. M. Binding of monoclonal antibody A2B5 to gangliosides. *Biochem. Biophys. Res. Commun.* **116**, 836–842 (1983). doi:10.1016/S0006-291X(83)80218-6
523. Sasaki, N., Itakura, Y. & Toyoda, M. Ganglioside GM1 contributes to the state of insulin resistance in senescent human arterial endothelial cells. *J. Biol. Chem.* **290**, 25475–25486 (2015). doi:10.1074/jbc.M115.684274
524. Lyczek, A. *et al.* Transplanted human glial-restricted progenitors can rescue the survival of dysmyelinated mice independent of the production of mature, compact myelin. *Exp. Neurol.* **291**, 74–86 (2017). doi:10.1016/j.expneurol.2017.02.005
525. Mason, J. L. & Goldman, J. E. A2B5+ and O4+ cycling progenitors in the adult forebrain white matter respond differentially to PDGF-AA, FGF-2, and IGF-1. *Mol. Cell. Neurosci.* **20**, 30–42 (2002). doi:10.1006/mcne.2002.1114
526. Fancy, S. P. J. *et al.* Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. *Genes Dev.* **23**, 1571–1585 (2009). doi:10.1101/gad.1806309
527. Hughes, A. N. & Appel, B. Oligodendrocytes express synaptic proteins that modulate myelin sheath formation. *Nat. Commun.* **10**, (2019). doi:10.1038/s41467-019-12059-y
528. Sahel, A. *et al.* Alteration of synaptic connectivity of oligodendrocyte precursor cells following demyelination. *Front. Cell. Neurosci.* **9**, (2015). doi:10.3389/fncel.2015.00077
529. Sakry, D., Karram, K. & Trotter, J. Synapses between NG2 glia and neurons. *Journal of Anatomy* **219**, 2–7 (2011). doi:10.1111/j.1469-7580.2011.01359.x
530. Beiter, R. *et al.* Evidence for oligodendrocyte progenitor cell heterogeneity in the adult mouse brain. *bioRxiv* 2020.03.06.981373 (2020). doi:10.1101/2020.03.06.981373
531. George, N. I. & Chang, C. W. DAFS: A data-adaptive flag method for RNA-sequencing data to differentiate genes with low and high expression. *BMC Bioinformatics* **15**, (2014). doi:10.1186/1471-2105-15-92
532. Ritchie, M. E. *et al.* Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015). doi:10.1093/nar/gkv007
533. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. *Omi. A J. Integr. Biol.* **16**, 284–287 (2012). doi:10.1089/omi.2011.0118
534. Fünfschilling, U. *et al.* Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. *Nature* **485**, 517–521 (2012). doi:10.1038/nature11007
535. Chittajallu, R., Aguirre, A. & Gallo, V. NG2-positive cells in the mouse white and grey matter display distinct physiological properties. *J. Physiol.* **561**, 109–122 (2004). doi:10.1113/jphysiol.2004.074252
536. Peterson, J. W., Bø, L., Mørk, S. J., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. *Ann. Neurol.* **50**, 389–400 (2001). doi:10.1002/ana.1123
537. Barkovich, A. J., Kjos, B. O., Jackson, D. E. & Norman, D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. *Radiology* **166**, 173–180 (1988). doi:10.1148/radiology.166.1.3336675
538. Ballesteros, M. C., Hansen, P. E. & Soila, K. MR imaging of the developing human brain. Part 2. Postnatal development. *Radiographics* **13**, 611–622 (1993). doi:10.1148/radiographics.13.3.8316668
539. Bird, C. R. *et al.* MR assessment of myelination in infants and children: usefulness of marker sites. *Am. J. Neuroradiol.* **10**, (1989).
540. van der Knaap, M. S. & Valk, J. MR imaging of the various stages of normal myelination during the first year of life. *Neuroradiology* **31**, 459–470 (1990). doi:10.1007/BF00340123
541. Boggs, J. M. & Moscarello, M. A. A comparison of composition and fluidity of multiple sclerosis and normal myelin. *Neurochem. Res.* **5**, 319–336 (1980). doi:10.1007/BF00964620
542. Gonsalvez, D. *et al.* The dynamics of oligodendrocyte generation: how distinct is the mouse from the human? *bioRxiv* 2019.12.23.887174 (2019). doi:10.1101/2019.12.23.887174
543. Choe, Y., Huynh, T. & Pleasure, S. J. Migration of oligodendrocyte progenitor cells is controlled by transforming growth factor β family proteins during corticogenesis. *J. Neurosci.* **34**, 14973–14983 (2014). doi:10.1523/JNEUROSCI.1156-14.2014
544. Nakahira, E., Kagawa, T., Shimizu, T., Goulding, M. D. & Ikenaka, K. Direct evidence that ventral forebrain cells migrate to the cortex and contribute to the generation of cortical myelinating oligodendrocytes. *Dev. Biol.* **291**, 123–131 (2006). doi:10.1016/j.ydbio.2005.12.010
545. Chandran, S. *et al.* FGF-dependent generation of oligodendrocytes by a hedgehog-independent pathway. *Development* **130**, 6599–6609 (2003). doi:10.1242/dev.00871
546. Rosenberg, S. S., Kelland, E. E., Tokar, E., De la Torre, A. R. & Chan, J. R. The geometric and spatial constraints of the microenvironment induce oligodendrocyte differentiation. *Proc. Natl. Acad. Sci.* **105**, 14662–7 (2008). doi:10.1073/pnas.0805640105
547. Kirby, B. B. *et al.* In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development. *Nat. Neurosci.* **9**, 1506–1511 (2006). doi:10.1038/nn1803
548. Santos, A. K. *et al.* Decoding cell signalling and regulation of oligodendrocyte differentiation. *Seminars in Cell and Developmental Biology* **95**, 54–73 (2019). doi:10.1016/j.semcdb.2018.05.020
549. Neumann, B. *et al.* Problems and pitfalls of identifying remyelination in multiple sclerosis. *Cell Stem Cell* **26**, 617–619 (2020). doi:10.1016/j.stem.2020.03.017
550. Orthmann-Murphy, J. L. *et al.* Remyelination alters the pattern of myelin in the cerebral cortex. *Elife* **9**, 1–61 (2020). doi:10.7554/eLife.56621
551. Bacmeister, C. M. *et al.* Motor learning promotes remyelination via new and surviving oligodendrocytes. *Nat. Neurosci.* **23**, 819–831 (2020). doi:10.1038/s41593-020-0637-3
552. Franklin, R. J. M., Frisén, J. & Lyons, D. A. Revisiting remyelination: Towards a consensus on the regeneration of CNS myelin. *Semin. Cell Dev. Biol.* (2020). doi:10.1016/j.semcdb.2020.09.009
553. Dwyer, C. M. *et al.* Multiple sclerosis as a syndrome—Implications for future management. *Front. Neurol.* **11**, 784 (2020). doi:10.3389/fneur.2020.00784
554. Newcombe, J., Cuzner, M. L., Røytta, M. & Frey, H. White matter proteins in multiple sclerosis. *J. Neurochem.* **34**, 700–708 (1980). doi:10.1111/j.1471-4159.1980.tb11200.x

555. Yu, R. K., Ueno, K., Glaser, G. H. & Tourtellotte, W. W. Lipid and protein alterations of spinal cord and cord myelin of multiple sclerosis. *J. Neurochem.* **39**, 464–477 (1982). doi:10.1111/j.1471-4159.1982.tb03968.x
556. Göpfert, E., Pytlik, S. & Debuch, H. 2', 3'-Cyclic Nucleotide 3'-Phosphohydrolase and lipids of myelin from multiple sclerosis and normal brains. *J. Neurochem.* **34**, 732–739 (1980). doi:10.1111/j.1471-4159.1980.tb11205.x
557. Clausen, J. & Hansen, I. B. Myelin constituents of human central nervous system: studies of phospholipid, glycolipid, and fatty acid pattern in normal and multiple sclerosis brains. *Acta Neurol. Scand.* **46**, 1–17 (1970). doi:10.1111/j.1600-0404.1970.tb05601.x
558. Woelk, H. & Borri, P. Lipid and fatty acid composition of myelin purified from normal and MS brains. *Eur. Neurol.* **10**, 250–260 (1973). doi:10.1159/000114281
559. Fewster, M. E., Hirono, H. & Mead, J. F. Lipid composition of myelin in multiple sclerosis. *J. Neurol.* **213**, 119–131 (1976). doi:10.1007/BF00313273
560. Suzuki, K., Kamoshita, S., Eto, Y., Tourtellotte, W. W. & Gonatas, J. O. Myelin in multiple sclerosis: composition of myelin from normal-appearing white matter. *Arch. Neurol.* **28**, 293–297 (1973). doi:10.1001/archneur.1973.00490230029002
561. Cumings, J. N. & Goodwin, H. Sphingolipids and phospholipids of myelin in multiple sclerosis. *Lancet* **292**, 664–665 (1968). doi:10.1016/S0140-6736(68)92510-5
562. Wolfgram, F. Multiple Sclerosis: Immunology, virology, and ultrastructure. (1972).
563. Kishimoto, Y., Radin, N. S., Tourtellotte, W. W., Parker, J. A. & Itabashi, H. H. Gangliosides and glycerophospholipids in multiple sclerosis white matter. *Arch. Neurol.* **16**, 44–54 (1967). doi:10.1001/archneur.1967.00470190048006
564. Wender, M., Filipek-Wender, H. & Stanisławska, J. Cholesteryl esters of the brain in demyelinating diseases. *Clin. Chim. Acta* **54**, 269–275 (1974). doi:10.1016/0009-8981(74)90245-9
565. Cuzner, M. L. & Davison, A. N. Changes in cerebral lysosomal enzyme activity and lipids in multiple sclerosis. *J. Neurol. Sci.* **19**, 29–36 (1973). doi:10.1016/0022-510X(73)90053-1
566. Natrajan, M. S. *et al.* Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. *Brain* **138**, 3581–3597 (2015). doi:10.1093/brain/awv289
567. Karamita, M. *et al.* Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. *JCI insight* **2**, (2017). doi:10.1172/jci.insight.87455
568. Zabala, A. *et al.* P2X₄ receptor controls microglia activation and favors remyelination in autoimmune encephalitis. *EMBO Mol. Med.* **10**, (2018). doi:10.15252/emmm.201708743
569. Zorina, Y., Stricker, J., Caggiano, A. O. & Button, D. C. Human IgM antibody rHlgM22 promotes phagocytic clearance of myelin debris by microglia. *Sci. Rep.* **8**, 1–14 (2018). doi:10.1038/s41598-018-27559-y
570. Cignarella, F. *et al.* TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. *Acta Neuropathol.* **140**, 513–534 (2020). doi:10.1007/s00401-020-02193-z
571. Laflamme, N. *et al.* mCSF-induced microglial activation prevents myelin loss and promotes its repair in a mouse model of multiple sclerosis. *Front. Cell. Neurosci.* **12**, 178 (2018). doi:10.3389/fncel.2018.00178